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ABSTRACT 
KINETICS AND MECHANISMS OF ACCUMULATION FOR LIPOSOMAL 
CIPROFLOXACIN INTO RAT ALVEOLAR MACROPHAGES 
 
By Sayeed Muhammad Mossadeq, B.Tech. 
 
A thesis submitted in partial fulfillment of the requirements for the degree of Master of Science 
at Virginia Commonwealth University 
 
Virginia Commonwealth University, 2013 
 
Major Director: Masahiro Sakagami, PhD. 
Associate Professor, Department of Pharmaceutics 
School of Pharmacy 
 
 
The kinetics and mechanism of accumulation for liposomal ciprofloxacin (Lipo-CPFX) into the 
rat alveolar macrophage NR8383 cells were studied in vitro, in comparison to unformulated 
ciprofloxacin (CPFX). Upon incubation with CPFX or Lipo-CPFX, cellular drug accumulation 
was determined from the cell lysates or efflux was from the extracellular media by fluorescence-
HPLC. The accumulation for Lipo-CPFX reached the asymptotic values at ≥ 2 hours, which was 
a result of uptake and efflux. The uptake appeared to be due to liposomes, mediated via cellular 
energy-independent mechanism like lipid fusion. In contrast, the efflux appeared to be due to 
ciprofloxacin, partly cellular energy-dependent, and involve probenecid-sensitive multidrug 
resistance proteins (MRPs). Overall, Lipo-CPFX enabled greater drug accumulation into the 
xiv 
 
 
 
NR8383 cells than CPFX. This logically suggests a greater potential to treat respiratory 
infections especially caused by bacteria resistant to phagocytic killing.                                                                                
1 
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CHAPTER 1 
 
BACKGROUND AND SIGNIFICANCE 
 
 
 
1.1 Respiratory infections: impact on health and need for treatment  
 
Respiratory infections are one of the most serious lung diseases in the world. It is presently 
ranked as the 8
th
 major cause of death, estimating 1.4 million children dying every year [World 
Health Organization, 2012; Murphy, 2012]. The respiratory infections are classified to upper and 
lower respiratory tract infections (URTIs and LRTIs, respectively). While URTIs are mostly self-
limiting viral infections, LRTIs are characterized by bacterial infections that can be severe, life 
threatening and thus more serious than URTIs [Ortqvist, 2002]. Pneumonia is a collective term 
for such severe and life threatening bacterial infections of the lower respiratory tract. The major 
and common pathogens known to cause LRTIs are Streptococcus pneumoniae, Mycoplasma 
pneumoniae, Legionella, Streptococcus pyogenes, Staphylococcus aureus, and Chlamydia 
 
 
2 
 
pneumoniae. Respiratory infections, especially LRTIs, cause significant impact on the health of 
the society, because they can spread quickly within the community, which thus requires frequent 
hospital admissions and large amounts of medical resources for the treatment [Ortqvist, 2002]. In 
patients with chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF), LRTIs are 
especially riskier, as their decreased mucus clearance can promote bacterial growth and sustain 
infections for further exacerbations [Wilson, 1998]. Hence, LRTIs still need investment and 
research for novel drug discovery and delivery for effective prevention and treatment.  
 
1.2 Antibiotic treatment for respiratory infections  
 
Antibiotics are generally recommended as a treatment in an early stage of LRTIs to avoid a risk 
of morbidity, especially in patients with COPD and CF [Ortqvist, 2002]. The first-line antibiotics 
recommended for the treatment of LRTIs are β-lactam antibiotics like amoxicillin, and 
tetracyclines [Woodhead et al, 2005]. The β-lactam antibiotics interfere with the peptidoglycan 
synthesis that is required to maintain bacterial cell wall integrity [Clark et al, 2005, Mayers et al, 
2009]; whereas the tetracyclines exert their antimicrobial activity by inhibiting bacterial protein 
synthesis via binding on the bacterial ribosome [Clark et al, 2005, Mayers et al, 2009]. However, 
the use of these first-line antibiotic agents requires careful attention to a development of 
resistance against certain respiratory pathogens. For instance, amoxicillin encounters resistance 
to bacteria such as Streptococcus pneumoniae which is the commonly encountered pathogen in 
pneumonia. Other β-lactam antibiotics such as penicillin, ampicillin, methicillin, and 
cephalosporines, also develop resistance from the common respiratory pathogens causing LRTIs. 
Moreover, these β-lactam antibiotics are ineffective against Mycoplasma pneumoniae, as the 
 
 
3 
 
organism lacks a cell wall [Clark et al, 2005, Mayers et al, 2009], which is a significant 
drawback in the treatment of LRTIs. Similarly, the frequent use of tetracyclines has also resulted 
in emergence of resistant bacterial strains. Bacteria are known to become resistant to 
tetracyclines by active efflux of the drug, bacterial ribosome protection and enzymatic 
inactivation of tetracycline [Speer et al, 1992]. 
Meanwhile other classes of antibiotics like aminoglycosides that include kanamycin, 
streptomycin, gentamicin, and tobramycin, have been used in LRTIs specifically caused by 
Pseudomonas and Staphylococci, by virtue of their antibacterial activity via inhibition of 
bacterial protein synthesis. However, their use has been also limited due to their potential renal 
toxicity and greater incidence of hearing impairment as a result of the auditory nerve damage 
[Schrier, 2007]. Chloramphenicol is also an inhibitor of bacterial protein synthesis and appears to 
have very high effectiveness for treating respiratory infections [Ioannidis et al, 1957, Clark et al, 
2005, Mayers et al, 2009]. However, it causes significant adverse effects such as aplastic anemia 
due to inhibition of blood forming cells in the bone marrow; because of this, its use now 
becomes rather rare in the treatment of respiratory infections [Ioannidis et al, 1957].  
The other class of antibiotics that inhibit bacterial protein synthesis is macrolides and has been 
used to treat respiratory infections. However, these macrolides also develop resistance against 
respiratory pathogens like Streptococcus pneumoniae, Streptococcus pyogenes [Clark et al, 2005, 
Mayers et al, 2009]. Finally, Sulfonamides and trimethoprim which were once used effectively 
against respiratory pathogens like S.pneumoniae have now become ineffective, again due to 
resistance in these bacterial strains; sulfonamides also cause serious hypersensitivity and blood 
dyscrasias [Huovinen, 2001].  
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1.3 Fluoroquinolones: chemistry and their choice for treating respiratory infections 
 
Fluoroquinolones are a newer class of antibiotics and presently used as the second-line 
antibiotics in the treatment of respiratory infections after the first-line antibiotics are found to be 
less effective or ineffective, including development of resistance [Jack, 2010]. Fluoroquinolones 
(Figure 1.1) exert broad spectrum antibacterial activity against both gram positive and gram 
negative bacteria. Differing from other classes of antibiotics, their mechanism of action is by 
inhibition of DNA gyrase and topoisomerase enzymes that are required for DNA replication and 
transcription [Zhanel et al, 2002]. This different mechanism of action is believed to contribute to 
lower resistance development against respiratory pathogens, compared to the first-line 
antibiotics. 
Chemically, fluoroquinolones are derived from nalidixic acid, which was the first synthetic 
quinolone antibiotic used against gram negative and gram positive bacteria. Almost all of the 
fluoroquinolones have been developed by modifying nalidixic acid, aiding for better efficacy and 
safety profiles. They have in common the quinolone structure with nitrogen (N-1), carboxylic 
acid at C-3, ketone at C-4 and fluorine atom at C-6, as shown in Figure 1.1 [Zhanel et al, 2002]. 
However, each of the fluoroquinolones differs in their physicochemical and antimicrobial 
properties as a result of structural modifications at the carbon positions of 1, 5, 7 and 8, as 
described in Figure 1.2. These structures are the main backbone, responsible for most of the 
antibacterial activities.  
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Figure 1.1 Chemical structure of different fluoroquinolones [Zhanel et al, 2002] 
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Figure 1.2 Structure-activity relationships of fluoroquinolones [Zhanel et al, 2002] 
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Fluoroquinolones are prescribed especially when patients fail to respond to the first-line 
antibiotics or are infected with pathogens resistant to, and/or cannot tolerate, other antibiotics 
[Williams, 2001]. In the meta-analysis by Vardakas et al (2008), fluoroquinolone antibiotics 
were reported to be superior over other antibiotics such as the macrolide and β-lactam 
antibiotics, in the treatment of community acquired pneumonia. This is primarily because they 
exhibit lower minimum inhibitory concentrations, e.g., MIC90, against different bacterial 
pathogens than other classes of antibiotics like penicillins, macrolides, and cephalosporins [Obaji 
et al, 2001]. In addition, unlike β-lactam antibiotics, fluoroquinolones are effective against 
pathogens that lack cell walls, such as Mycoplasma pneumoniae. The bacteriological response of 
fluoroquinolones to some common respiratory pathogens has also been reported to be superior 
over other antibiotics classes [Obaji et al, 2001]. As a result, their patient compliance becomes 
high and the length of hospital stay can be shortened. Therefore, fluoroquinolones are better 
second-line antibiotics especially when LRTIs are not successfully treated with the first-line 
antibiotics. 
 
1.4 Ciprofloxacin for respiratory infections 
 
Ciprofloxacin is one of the widely marketed and used antibiotics among the fluoroquinolones 
against LRTIs by virtue of its wide spectrum antimicrobial activity and lower toxicity compared 
to other fluoroquinolones [Hooper et al, 2013]. Indeed, many of the other fluoroquinolones have 
been withdrawn from the market due to adverse effects. For example, the cardiac toxicity for 
grepafloxacin, hepatic toxicity for trovafloxacin, frequent hyper & hypoglycemia with 
gatifloxacin, frequent rashes for gemifloxacin, have all led to the withdrawal of these newer 
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generation fluoroquinolones. Ciprofloxacin is an antibiotic of choice for the treatment of LRTIs 
especially when the life-threatening risk of pseudomonas aeruginosa is suspected or present, by 
virtue of its higher potency against this organism compared to the other fluoroquinolones 
[Hooper et al, 2013; Woodhead et al, 2005]. 
Chemically, ciprofloxacin (Figure 1.1) was modified on the quinolone structure by substitution 
of a cyclopropyl ring at the N-1 position, a fluorine atom at the C-6 position and a piperazine at 
the C-7 position. Its antibacterial activity is mainly due to the carboxylic acid (-COOH) at C-3, 
ketone (-C=O) at C-4, fluorine at C-6. The carboxylic acid and ketone groups are responsible for 
the binding to bacterial gyrase and transport into the bacteria, while the fluorine is responsible 
for the DNA-gyrase inhibition and bacterial cell penetration. Its steric bulk of the cyclopropyl 
ring at N-1 serves as an optimum substitution for enhancing the antibacterial activity. In addition, 
the piperazine at C-7 improves the activity against gram negative bacteria and increases the half-
life and aqueous solubility [Zhanel et al, 2002].  
Ciprofloxacin (molecular weight 331.4) has two pKa values of 6.0 and 8.8 and exists as a zwitter 
ion at a physiological pH of 7.4. This has been advocated for its reasonable transport across 
biological membranes, enabling higher intracellular drug concentrations [Shek, 1995]. 
Ciprofloxacin has been reported as the most potent antibiotic against Pseudomonas aeruginosa 
[Oliphant, 2002] and penicillin/macrolide-resistant Streptococcus pneumoniae [Jones, 2002]. 
Ciprofloxacin is also a drug of choice among other fluoroquinolones for treating against other 
common and lethal respiratory pathogens such as Francisella tularensis (Tularemia) and 
Bacillus anthracis (Anthrax) [Oliphant, 2002]. In addition to these better antimicrobial profiles, 
ciprofloxacin also shows favorable pharmacokinetic profiles following oral and intravenous 
administration. Ciprofloxacin exhibits linear pharmacokinetics upon oral or intravenous 
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administration, thus enabling its serum levels for microbicidal activity predictable and 
controllable [Bergan et al, 1988]. The oral bioavailability of ciprofloxacin is 70-85 % [Bergan et 
al, 1988], indicating that the drug is well absorbed through the gastrointestinal tract. The volume 
of distribution of ciprofloxacin after intravenous injection has been reported to be 2-3-fold higher 
than the total body fluid volume, suggesting that the drug is well distributed and penetrated 
throughout the body tissues, perhaps including the lung [Bergan et al, 1988]. In fact, following 
oral and intravenous administration, ciprofloxacin has been reported to achieve 3.5-fold higher 
lung concentrations, compared to the serum concentration [Bergan et al, 1988]. Thus, 
ciprofloxacin possesses favorable antimicrobial and pharmacokinetic properties for effective 
treatments of LRTIs. 
 
1.5 A need for targeting drugs to the alveolar macrophages  
 
In theory, antibiotics such as ciprofloxacin should be accumulated at the sites of microbial 
infection and accumulation. For respiratory infections, such sites are within the lung, as most of 
bacterial pathogens make an entry through the lung. In addition, when considering the 
intracellular pathogens that can infect the lungs, targeting the drugs preferentially to the sites 
where pathogens multiply to worsen infectious conditions is logically critical for their 
therapeutic outcome. In this context, the lung lining fluid is considered as the primary site of 
multiplication, while some respiratory pathogens such as S. pneumoniae, H. influenza, B. 
anthracis, N. meningitidis, K. pneumoniae, Staphylcoccus aureus, Mycobacterium tuberculosis, 
and Legionella pneumophila have been known to evade microbicidal mechanisms for survival 
and multiplication upon accumulation in the alveolar macrophages [Blanchard, 2006]. This 
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survival of microbes within the macrophages is a more serious concern for respiratory infections 
in patients with COPD or CF. Therefore, survival and multiplication of pathogens inside the 
alveolar macrophages would be more detrimental to such COPD and CF patients. Thus, the 
antibiotic targeting to the alveolar macrophages has become of great interest in the treatment of 
respiratory infections.  
 
1.6 Pulmonary delivery of ciprofloxacin  
 
Ciprofloxacin is currently administered by the oral and intravenous (IV) routes for the treatment 
of respiratory infections. Although oral or IV administration enable the drug to reach the lungs, 
these routes are not best suited to target the drug selectively to the lung tissues and alveolar 
macrophages for efficient local bactericidal effects. Following oral and IV administration, 
ciprofloxacin was shown to be eliminated with a half-life of 3-4 hours [Pedersen, 1989]. Given 
the potential importance of targeting ciprofloxacin to the alveolar macrophages, as described 
above, these oral and IV routes of administration may not be the best for the treatment of 
respiratory infections. Indeed, Chono et al (2007) investigated the pharmacokinetics of oral and 
pulmonary administration of ciprofloxacin in rats, and found that the drug delivery to the 
alveolar macrophages was superior with pulmonary administration, compared to oral 
administration. However, such pulmonary administration of ciprofloxacin did not sustain the 
local ciprofloxacin levels for a longer period, such as 24 hours.  
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1.7 Targeted drug delivery strategies to the alveolar macrophages 
 
Several attempts have been made to target drug delivery to the alveolar macrophages, mostly 
using drug carriers. The most popular drug carriers are polymeric particles, solid lipid 
nanoparticles (SLNs), dendrimers and liposomes [Zhang et al., 2010]. These drug carriers have 
been tested for effective delivery of therapeutic agents to the alveolar macrophages, aiming for 
better therapeutic efficacy, compared to unformulated drugs. Among them, the polymeric 
carriers have been prepared from a wide variety of polymers including poly(lactic acid) (PLA), 
poly(glycolic acid) (PGA), poly(lactide-co-glycolide) (PLG), poly(butylcyanoacrylate) (PBCA), 
polyalkyl acrylates (PAC), and polymethyl methacrylate (PMCA). Skidan et al (2003) reported 
that rifampicin loaded in PBCA nanoparticles enabled increased drug delivery to the 
macrophages, enhancing bactericidal activity against Staphylococcus aureus and Mycobacterium 
avium. SLNs are composed of lipids that are solids at room temperature together with surfactants 
for lipid stabilization. Pandey et al (2005) reported superior pharmacokinetics and anti-microbial 
effects of SLNs encapsulating anti-tubercular drugs against Mycobacterium tuberculosis in 
guinea pigs. Intrapulmonary administration of rifampin-loaded SLNs to guinea pigs infected with 
Mycobacterium tuberculosis resulted in higher drug levels and superior bacterial clearance in the 
lungs, compared to pulmonary administration of free rifampin. Dendrimers are branched 
macromolecules mostly composed of polyamidoamine (PAMAM). Their branched structures 
offer greater surface areas for interaction with the cells and therefore greater probability of 
cellular internalization. Ma et al (2007) demonstrated greater antibacterial effects of 
sulfamethoxazole against E-coli with the PAMAM dendrimers, compared to its solution form, 
attributed to higher penetration of the dendrimer into the bacteria.  
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Although these polymeric carriers, SLNs and dendrimers have all shown positive in vitro and in 
vivo results as to drug targeting to the bacteria in the alveolar macrophages, they are still in an 
investigational stage, far prior to clinical trials. In this context, liposomes are the phospholipid 
bilayer based drug carriers that have been available in the marketed products for human use, such 
as Doxil for cancer therapy with doxorubicin, DaunoXome for cancer therapy with daunorubicin 
and Abelcet, Ambisome and Amphitec for the treatment of fungal infections with amphotericin 
[Cipolla et al, 2012]. Thus, the use of liposomes as drug carriers to deliver/target drugs like 
ciprofloxacin to the alveolar macrophages may be a low-risk strategy to achieve higher 
intracellular drug levels to combat facultative intracellular respiratory pathogens in LRTIs. 
 
1.8 Liposomes for targeting ciprofloxacin delivery to the alveolar macrophages 
 
Liposomes are composed of phospholipids bilayers with compositions similar to the plasma 
membrane of the cells. It is believed that this lipid bilayer composition enables uptake by the 
biological membranes, while likely being regarded less toxic compared to polymeric carriers. 
Liposomes are generally prepared by the thin film hydration method, where a thin lipid film is 
formed via evaporation of an organic solvent dissolving the lipids. For a hydrophilic drug, its 
aqueous solution is added to the organic solvent for encapsulation in the inner aqueous cores via 
formation of multi-lamellar liposomes. For a hydrophobic drug, the drug is dissolved in the 
organic solvent along with the lipids, such that evaporation of the organic phase and subsequent 
addition of an aqueous phase result in the drug’s encapsulation in the lipid bilayers. In these 
ways, liposomes can encapsulate hydrophilic drugs in their inner aqueous core and hydrophobic 
drugs in their lipid bilayers. 
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Alternatively, drugs can be loaded into the liposomes by trans-membrane ion gradients. In this 
method, liposomes are first prepared as empty liposomes, yet with certain ions in the aqueous 
inner phase to later create ionic imbalance. Because only unionized and net charge-neutral form 
can diffuse across the liposome’s lipid bilayers, charged molecules are trapped inside the 
liposomes, while unionized and/or net charge-neutral molecules are released from the liposomes. 
This method has been used for ciprofloxacin [Shek et al, 1995] in which egg 
phosphatidylcholine/cholesterol liposomes were prepared, containing ammonium sulfate within 
the inner aqueous core phase. Because ammonium ion (NH4
+
) dissociates to the uncharged 
ammonia (NH3) that can diffuse through the liposomal phospholipid bilayers to the external 
media, the intra-liposomal pH is reduced to a pH that is 3 units lower than the external neutral 
pH [Shek 1995]. Accordingly, unionized or net charge-neutral form of ciprofloxacin can diffuse 
into the liposomes where it gets protonated and thus trapped inside the liposomes (acid trap).  
Liposomes have been shown to be taken up by the freshly isolated rat alveolar macrophages in 
vitro and also to cause reduced systemic exposure, and increased drug uptake into the target cells 
[Gonzalez-Rothi et al, 1990, Schreier H., 2001]. McCullough et al (1980) showed in a rat study 
that intratracheal instillation of liposomes encapsulating cytosine arabinoside (an anti-neoplastic 
compound) enabled longer retention within the lungs, and reduced systemic exposure, compared 
to solution administration. Poyner et al (1995) also reported longer retention of tobramycin in the 
lungs of rats following endotracheal instillation of liposomal tobramycin. At 24 hours following 
instillation, 55 % of the liposomal tobramycin remained in the lungs, compared to only 5 % of 
the drug in solution. In the same study, the PLA microspheres loaded with tobramycin were 
shown to retain lower 46 % of the drug in the lungs, demonstrating a greater benefit of the 
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liposomes, compared to the PLA microspheres. Indeed, PLA microspheres can be more toxic, 
causing lung inflammation [Armstrong et al., 1996].  
Hence, these earlier studies have shown some benefits of liposomal drugs with sustained 
retention in the lung. Meanwhile, liposomes can be prepared in different sizes and generally 
classified as multilamellar vesicles (MLVs – 400-3500 nm), large unilamellar vesicles (LUVs – 
50-1000 nm) and small unilamellar vesicles (SUVs – 25-50 nm) [Ostro, 1983]. Thus, compared 
to other drug carriers, liposomes can be advantageous in that targeting efficiencies can be made 
possibly in a custom fashion, as changing liposome size and lipid composition can greatly 
influence their interactions with the alveolar macrophages. For instance, liposomes in a size of 
1000 nm have been reported to be more preferentially taken up by the rat alveolar macrophages 
among different sizes [Chono et al, 2006]. Likewise, altered lipid composition can also influence 
the uptake of the liposomes by the alveolar macrophages. For example, inclusion of phosphatidyl 
serine in the liposome has been reported to enhance liposome uptake by the rat alveolar 
macrophages [Fidler, 1985]. Surface modification of liposomal surface with mannose has been 
shown to enhance the accumulation by adding mannose specific receptor-mediated macrophage 
uptake [Wijagkanalan et al, 2008]. Overall, liposomes possess unique physicochemical 
properties to overcome physiological, formulation and pharmacokinetic challenges of other drug 
carriers to enable targeted drug delivery to the alveolar macrophage.  
The in vivo advantages of liposomal ciprofloxacin over unformulated ciprofloxacin in solution 
have been demonstrated by Chono et al, 2008. Pulmonary administration of liposomal 
ciprofloxacin was capable of achieving higher ciprofloxacin levels in the alveolar macrophages 
for a longer 24 hour period, compared to free ciprofloxacin. For other drugs, Wichert et al. 
(1992) also demonstrated superior in vitro targeting efficiency of liposomes to deliver amikacin 
 
 
15 
 
to the alveolar macrophages infected with Mycobacterium avium-intracellulare, exhibiting 100-
fold greater killing efficacy. In another in vivo study [Conley et al, 1997], aerosolized liposomes 
encapsulating ciprofloxacin resulted in the survival of all mice for 16 days against Francisella 
tularensis infection. This was quite a contrast to infected mice receiving free ciprofloxacin, as all 
were reported dead within 9 days. It should be noted that Francisella tularensis is a facultative 
intracellular bacterium that can survive and multiply inside the alveolar macrophages [Conley et 
al, 1997]. Thus, this survival superiority for liposomal ciprofloxacin is a strong indication for the 
therapeutic benefits of enhanced drug targeting to the alveolar macrophages.  
In light of these greater therapeutic potentials, Aradigm Corporation (Hayward, CA) is presently 
developing liposomal ciprofloxacin (Lipo-CPFX) for inhalation to treat respiratory infections in 
patients with CF and bronchiectasis. Lipo-CPFX was prepared by the lipid film hydration 
method and acid loading by an ammonium sulfate gradient [Cipolla et al, 2012]. Briefly, 
hydrogenated soy phosphatidylcholine (70.6 mg/ml) and cholesterol (29.4 mg/ml) were first 
dissolved in ethanol, followed by evaporation of the organic solvent at 37-40 
o
C. Ammonium 
sulfate solution was added to the lipid film in order to form multi lamellar vesicles (MLVs) 
containing ammonium sulfate. These MLVs were passed through a series of membrane filters 
with progressively smaller pore size in order to prepare small unilamellar vesicles (SUVs) in an 
averaged size of 100 nm. Ciprofloxacin was then added to the SUV suspension with vigorous 
stirring and incubated at 60 
o
C for 2 hours. This resulted in the unionized form and/or net charge-
neutral form of ciprofloxacin diffusing into the liposomes, while ammonia releasing from the 
liposomal inner core. Following entry into the liposomes, ciprofloxacin was protonated and thus 
entrapped inside the liposomes.  
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The efficacy of Aradigm’s Lipo-CPFX was assessed in a mouse infection model of 
Pseudomonas aeruginosa [Cipolla et al, 2012]. Following intratracheal inoculation of mice with 
Pseudomonas aeruginosa-laden agarose beads, three aerosol doses of Lipo-CPFX (e.g 0.05 ml of 
5, 16.5 and 50 mg/ml Lipo-CPFX) were administered. Greater survival rates were observed with 
mice treated with Lipo-CPFX at all three doses, compared to the untreated control group [Cipolla 
et al, 2012]. Thus, pulmonary delivery of Lipo-CPFX appeared to be more efficacious to treat 
Pseudomonas aeruginosa infection, one of the most common pathogens causing respiratory 
infections in patients with CF and bronchiectasis.  
This Lipo-CPFX formulation has been also shown to reduce Pseudomonas aeruginosa loads in 
the lung of CF patients and is currently in phase II clinical trials in adult patients with non-CF 
bronchiectasis [Aradigm Press Release, 2012]. Following inhalation, Lipo-CPFX showed lower 
ciprofloxacin blood levels, compared to those following oral and IV administration [Aradigm 
Press Release, 2012]. The formulation has also been shown to enable sustained pharmacokinetics 
without significant adverse events in healthy volunteers following inhalation [Aradigm Press 
Release, 2012]. Even so, the lung disposition of Lipo-CPFX, specifically to the alveolar 
macrophages, has not yet been clearly assessed. Considering the accumulation and 
survival/multiplication of certain respiratory pathogens inside the alveolar macrophages, it would 
be of great interest to characterize and clarify the kinetics and mechanism for enhanced drug 
accumulation for Lipo-CPFX into the alveolar macrophages, compared to unformulated 
ciprofloxacin in solution. 
 
 
 
 
17 
 
1.9 Rationale to study Lipo-CPFX accumulation in the alveolar macrophages in vitro 
 
Lipo-CPFX is a particulate system that does not generally diffuse through the phospholipid 
bilayers of the alveolar macrophages, unlike unformulated ciprofloxacin. Therefore, compared to 
unformulated ciprofloxacin in solution, the cellular transport process for Lipo-CPFX must differ 
kinetically and mechanistically. In the alveolar macrophages, the transport mechanisms for 
particulates including liposomes are generally via endocytosis and/or lipid fusion, both of which 
take place upon interaction with the cellular phospholipid bilayers. Endocytosis is generally 
cellular energy-dependent which includes phagocytosis for particulates and pinocytosis for fluid 
solutes. On the other hand, lipid fusion is a process where liposomes can adhere to the plasma 
membrane directly, by virtue of similar phospholipid composition, thereby releasing the intra-
liposomal contents into the cytoplasm. Unlike endocytosis, lipid fusion can be cellular energy-
independent and thus may not be necessarily non-linear and saturable in the kinetics [Marchini et 
al, 2011; Batzri et al, 1975]. Alternatively, Lipo-CPFX may release ciprofloxacin outside the 
cells with or without its interaction with the cells; the released ciprofloxacin can then enter the 
alveolar macrophages by diffusion, pinocytosis or uptake transporters. Thus a number of 
mechanisms can exist for alveolar macrophagic accumulation for Lipo-CPFX. 
To characterize this possibly complex accumulation for Lipo-CPFX, in vivo systems may not be 
suited due to further complications derived from those other than the alveolar macrophages. 
Rather in vitro macrophage cell systems would be simpler for characterization and also allow 
manipulation to explore the accumulation mechanisms by using inhibitors of certain transports of 
interest. In fact, the alveolar macrophages freshly obtained from animals via the bronchoalveolar 
lavage (BAL) have been used as in vitro cell models to study the cellular disposition of a variety 
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of drugs and formulations. However, such an experimental model would require animal sacrifice 
in each experiment. Furthermore, freshly isolated cells may have caused marked inter- and intra-
animal variability in the accumulation kinetics. Hence, an in vitro system with continuous cell 
line culture would be more preferable, and such an experimental system was with the NR8383 
cells.  
The NR8383 cells were originally established as a continuous cell line upon isolation from the 
lung of male Sprague Dawley rats via BAL [ATCC product catalog, CRL-2192]. The cells 
display the macrophagic characteristics of phagocytosis and cytokine production, similar to their 
in vivo counterparts, yet in a more reproducible fashion. They are capable of phagocytosing 
P.aeruginosa (a live challenge) as well as zymosan particles, and secreting cytokines like 
interleukins, tumor necrosis factor and nitric oxide along with the surface expression of Fc 
receptors for certain Fc-based receptor mediated endocytosis [Helmke et al, 1989].  
Hence, in this thesis project, the NR8383 cells were used as the in vitro experimental model to 
investigate the kinetics and mechanisms of accumulation and efflux of Lipo-CPFX, compared to 
those for free ciprofloxacin (CPFX). It has been hypothesized that Lipo-CPFX enables greater 
accumulation of ciprofloxacin into the NR8383 cells by virtue of greater uptake mechanism 
differing from that for CPFX.  
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CHAPTER 2 
 
HYPOTHESIS AND SPECIFIC AIMS 
 
 
 
The aim of this thesis was to characterize the kinetics and mechanisms of CPFX and Lipo-CPFX 
accumulation into rat alveolar macrophages (NR8383 cells). By so doing, the greater potential of 
Lipo-CPFX in treating respiratory infections could be shown by virtue of its greater drug 
accumulation into the NR8383 cells. Overall, it was hypothesized that Lipo-CPFX enables 
greater accumulation of ciprofloxacin into alveolar macrophages, compared to CPFX, as a result 
of higher liposomal uptake despite comparable efflux. Accordingly, the project pursued the 
following specific aims using the rat alveolar macrophage cell line, NR8383 cells: 
 
1. To determine the time-course kinetics of CPFX and Lipo-CPFX accumulation 
 
2. To determine the concentration dependence on CPFX and Lipo-CPFX accumulation 
 
3. To determine the time-course kinetics of CPFX and Lipo-CPFX efflux  
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4. To clarify the uptake and efflux mechanisms for CPFX and Lipo-CPFX  
 
In Chapter 3, the time-course kinetics of accumulation and efflux of CPFX and Lipo-CPFX into 
the NR8383 cells will be studied in vitro. Ammonium chloride, which elevates the intra-cellular 
or intra-liposomal pH to release the encapsulated ciprofloxacin from the liposomes, will be used 
to identify the species of uptake for Lipo-CPFX. In addition to such characterization, the time-
course kinetics of efflux will also be examined to identify the species of efflux. By doing so, 
Chapter 3 will identify the uptake and efflux pathways Lipo-CPFX, in comparison to CPFX. In 
Chapter 4, more detailed investigations will be carried out to identify the mechanisms for the 
uptake and efflux of Lipo-CPFX as well as CPFX. The involvement of endocytosis or lipid 
fusion for the uptake will be studied, alongside the accumulation experiments at a reduced 
temperature, in the presence of ATP depleting agents and using inhibitors of certain membrane 
transports. Finally, Chapter 5 will describe the summary and overall conclusions of this thesis 
project.  
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CHAPTER 3 
 
IN VITRO KINETICS AND PATHWAYS OF CIPROFLOXACIN ACCUMULATION 
FOR CPFX AND LIPO-CPFX INTO RAT ALVEOLAR MACROPHAGE NR8383 
CELLS 
 
 
 
3.1 Introduction 
 
Ciprofloxacin is currently administered by the oral and intravenous routes for the treatment of 
respiratory infections [Louie 1994]. However, these routes may not enable sufficient drug 
accumulation into the lung, especially in the alveolar macrophages, in order to efficiently inhibit 
bacterial growth and/or kill bacteria. In contrast, direct local pulmonary delivery would be 
logically favorable to achieve sufficiently high drug concentrations in the lung and alveolar 
macrophages. Even so, in rat studies, ciprofloxacin was found to be cleared from the lung in 2-4 
 
 
22 
 
hours [Chono et al. 2007], and therefore, frequent administration would be required to maintain 
the drug level for a longer period.  
To challenge this deficiency, liposomal ciprofloxacin (Lipo-CPFX) is being developed by 
Aradigm Corporation to sustain drug concentrations within the lung for a longer period 
[Aradigm Press Release, 2012]. Chono et al (2008) also prepared liposomal ciprofloxacin and 
demonstrated sustained drug retention in the lung and greater accumulation in the alveolar 
macrophages following pulmonary administration in rats, compared to unformulated 
ciprofloxacin. Nevertheless, neither of the formulations was elaborated to determine and clarify 
the kinetics and pathways of ciprofloxacin accumulation into the alveolar macrophages. Hence, 
in this chapter, ciprofloxacin accumulation for Lipo-CPFX was kinetically characterized using 
the rat alveolar macrophage NR8383 cells in vitro, compared to that for unformulated 
ciprofloxacin in solution (CPFX). 
 
3.2 Materials and Methods 
 
3.2.1 Drugs and reagents 
 
Lipo-CPFX was a gift from Aradigm Corporation (Hayward, CA) for this research. It was 
received as 50 mg/ml ciprofloxacin hydrochloride liposomal suspension and stored at 4 
o
C. Prior 
to each experiment, Lipo-CPFX was diluted with phosphate-buffered saline (PBS, pH 7.4) to 
prepare designated concentrations. Ciprofloxacin hydrochloride (CPFX) was purchased from MP 
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Biomedicals (Solon, OH) and stored at 4 
o
C. PBS was used to dissolve and prepare designated 
concentrations of CPFX prior to each experiment. Ammonium chloride (NH4Cl) was purchased 
from Fisher Scientific (Pittsburg, PA) and dissolved in PBS to make a 50 mM solution.  
 
3.2.2 Rat alveolar macrophage NR8383 cell culture 
 
Rat alveolar macrophage NR8383 cells (passage 4) were obtained from the American Type 
Culture Collection (ATCC; Manassas, VA) and propagated in the 25 or 75 cm
2
 T-culture flasks 
(Corning Costar; Cambridge, MA), according to the ATCC protocol [Product Information Sheet, 
ATCC]. Briefly, they were seeded at a density of 0.1x10
6
 cells/cm
2
 in the flasks and respectively 
cultured in 10 or 20 ml of the Ham’s F-12K medium (ATCC; Manassas, VA) supplemented with 
15 % (v/v) heat-inactivated fetal bovine serum (FBS; Invitrogen, Carlsbad CA) and 1 % (v/v) 
penicillin/streptomycin (10,000 U/10 mg per ml; Sigma-Aldrich). The cells were maintained at 
37 
o
C, 95 % humidified air and 5 % CO2 in the incubator (Model 5410; NAPCO, Milliville, NJ); 
5 % CO2 was maintained via the CO2 cylinder (National Welders, Richmond, VA). The media 
were changed every other day, from which the floating cells were recovered by centrifugation 
(12,000 rpm for 2 minutes) and returned to the respective flasks. The cells were passaged every 5 
days following collection by scraping using a 25 cm long cell scraper (Corning, NY). Following 
centrifugation of the cell suspension at 1,000 rpm for 7 minutes, the supernatant was discarded 
and the cell pellets were re-suspended with freshly prepared media and split in 2 equal volumes 
into new 25 or 75 cm
2
 flasks and otherwise, plated in 24-well culture plates for experiments.  
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3.2.3 Ciprofloxacin accumulation for  CPFX and Lipo-CPFX into the NR8383 cells 
 
The NR8383 cells (passage 7-15) were seeded into 24-well culture plates at 0.2x10
6
 cells in each 
well with 0.2 ml of the Ham’s F-12K media supplemented with 1 % (v/v) FBS. The cells were 
cultured for 1 hour at 37 
o
C, 5 % CO2 and 95 % humidified air, to allow them to settle down in 
the wells. Subsequently, the media were removed and centrifuged at 12,000 rpm for 2 minutes to 
collect non-adherent floating cells. These floating cells were re-suspended with 1 ml of the 
CPFX solution or Lipo-CPFX suspension in PBS at designated concentrations and immediately 
added to the respective wells to commence accumulation into the cells in the incubator at 37 
o
C. 
At different times, the incubation media were taken and centrifuged at 12,000 rpm for 2 minutes 
to collect non-adherent cells. These cells were quickly washed with 1 ml of ice-cold PBS, 
followed by centrifugation for recovery as cell pellets. The pellets were lysed with 0.25 ml of 0.1 
M glycine·HCl solution (Sigma-Aldrich) adjusted to pH 3.0. In contrast, the adherent cells in the 
24-well plates were lysed with another 0.25 ml of 0.1 M glycine·HCl solution (pH 3.0) on an ice-
bath. The pipette tips were used to scrape off the cells from the well to complete their recovery. 
The lysates from the non-adherent and adherent cells (0.25 ml in each) were added, so that 
ciprofloxacin accumulation into 0.2x10
6
 NR8383 cells could be determined. The lysate (0.5 ml) 
was stored at -70 
o
C prior to the ciprofloxacin assay. For the accumulation studies, the cells were 
incubated with 10 - 200 µg/ml of CPFX and Lipo-CPFX for different times (5, 15, 30, 45, 60, 
120 and 240 minutes) at 37 
o
C. The cells were also pre-incubated for 10 minutes with 50 mM 
NH4Cl, followed by co-incubation of CPFX or Lipo-CPFX with 50 mM NH4Cl.  
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3.2.4 Efflux and/or release from the NR8383 cells following CPFX and Lipo-CPFX 
accumulation  
 
In order to study the efflux and release kinetics of ciprofloxacin from the NR8383 cells, CPFX 
and Lipo-CPFX were first incubated for 2 hours at 37 
o
C for accumulation into the cells. 
Subsequently, the incubated CPFX or Lipo-CPFX solution was removed and the cells were 
quickly washed with 1 ml of ice cold PBS on an ice bath. The efflux and/or release of 
ciprofloxacin were initiated and monitored upon addition of 1 ml of PBS at 37 
o
C in the 
incubator or at 4 
o
C in the refrigerator. At different times, 0.2 ml of the extracellular PBS was 
sampled and 0.2 ml of fresh PBS was added immediately for replenishment. At 240 minutes, the 
cells were washed with ice cold PBS and lysed with 0.5 ml of 0.1 M glycine·HCl solution (pH 
3.0) to recover ciprofloxacin remaining to be effluxed and released. The floating cells, if any, 
were recovered by spinning down at 12,000 rpm for 2 minutes and lysed together with the lysis 
solution for the adherent cells.  
 
3.2.5   Ciprofloxacin analysis and determination  
 
All samples taken from the above experiments were analyzed for determination of ciprofloxacin 
mass using high performance liquid chromatography (HPLC; Waters Corporation) coupled with 
a fluorescence detector [De Smet et al, 2009]. The mobile phase was comprised of 8.0 mM 
tetrabutylammonium bromide, 0.2 % (v/v) trifluoroacetic acid, 15 % (v/v) acetonitrile, 5 % (v/v) 
methanol and 79.8 % HPLC grade water and fed at a flow rate of 1 ml/min. Samples (10 µL) 
were injected onto a Spherisorb ODS-2 column (4.6 mm in diameter, 250 mm in length, 5 µm; 
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Alltech Associates Inc., Deerfield, IL). The excitation and emission wavelengths of 279 and 442 
nm, respectively, were used for ciprofloxacin detection. The assay was validated with respect to 
the linearity (R
2 
> 0.99) in the range of 5-200 ng/ml. The limit of quantitation (LOQ) of the assay 
was 5 ng/ml.  
 
3.2.6 Data and statistical analysis 
 
Ciprofloxacin mass in each sample was a product of the sample concentration determined by the 
HPLC method described above and the volume of the cell lysates or extracellular PBS samples. 
The ciprofloxacin mass accumulated into, and effluxed and/or released from, the NR8383 cells is 
described as the values normalized with 1 x 10
6
 NR8383 cells. The data are described as mean ± 
standard deviation (SD) with 3-4 replicates. Statistical analyses were carried out with one- or 
two-way analysis of variance (ANOVA) and dunnet’s post-hoc test, where a p-value < 0.05 was 
considered as significant. JMP 10 was used as the statistical software. 
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3.3. Results 
 
3.3.1 Cell passage-dependent accumulation for CPFX and Lipo-CPFX into the NR8383 
cells 
 
As the continuously cultured NR8383 cell line was used, the ciprofloxacin accumulation was 
first studied to see if the cell passage (P) in culture alters the accumulation. Figure 3.1 shows the 
ciprofloxacin mass accumulated into the NR8383 cells with different passages, P10 and P15, for 
120 minutes at 37 
o
C following application of CPFX and Lipo-CPFX at 140 µg/ml. For a given 
formulation (CPFX or Lipo-CPFX), the ciprofloxacin accumulation significantly differed (two-
way ANOVA, p < 0.05) in different cell passages, demonstrating cell passage-dependent 
accumulation. Compared to those with the lower passage (P10), the cells with the higher passage 
(P15) accumulated ciprofloxacin to 3.8±0.5- and 2.8±1.0-fold greater extents for CPFX and 
Lipo-CPFX, respectively. Likewise, Figure 3.2 shows the cell passage-dependent accumulation 
at 200 µg/ml, where 2.6±0.4- and 2.0±0.5-fold greater drug accumulation was seen for the P15 
cells compared to the P10 cells. These cell passage-dependent ciprofloxacin accumulations into 
the NR8383 cells demanded a use of passage-matched cells for the assessments of ciprofloxacin 
accumulation in this project. Because there were also significant differences in ciprofloxacin 
accumulation between the formulations, it was also suggested that the accumulation for CPFX 
and Lipo-CPFX differed kinetically and mechanistically, which were also cell passage 
dependent. Note however that interaction was not significant in two-way ANOVA. 
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Figure 3.1 Passage-dependent ciprofloxacin accumulation into the NR8383 cells for 120 
minutes at 37 
o
C following application of (a) CPFX and (b) Lipo-CPFX at 140 µg/ml. 
Data: mean ± SD (N=4). (*p <0.05) 
 
 
* 
(a) 
* (b) 
 
 
29 
 
 
 
Figure 3.2 Passage-dependent ciprofloxacin accumulation into the NR8383 cells for 120 
minutes at 37 
o
C following application of (a) CPFX and (b) Lipo-CPFX at 200 µg/ml. 
Data: mean ± SD (N=4). (*p <0.05) 
 
(b) 
(a) * 
* 
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3.3.2 Time-course accumulation profiles for CPFX and Lipo-CPFX into the NR8383 cells  
 
Figure 3.3 shows the time-course profiles of ciprofloxacin accumulation into the passage 
matched NR8383 cells (P10 or P15) at 37 
o
C following application of (a) CPFX and (b) Lipo-
CPFX at 10 and 200 g/ml. For CPFX and Lipo-CPFX, ciprofloxacin accumulation at 10 g/ml 
reached a comparable plateau level after 5 minutes (two-way ANOVA, p > 0.05), demonstrating 
rapid equilibrium in accumulation. In contrast, at 200 g/ml, the profiles appeared to be bi-
phasic for CPFX and Lipo-CPFX, where rapid accumulation was followed by efflux and/or 
release at ≥ 30 minutes, prior to reaching asymptotic plateau levels. Notably, Lipo-CPFX showed 
significantly greater accumulation than CPFX at 200 g/ml (two-way ANOVA, p < 0.05), 
suggesting different kinetics and mechanisms for ciprofloxacin accumulation between CPFX and 
Lipo-CPFX. The accumulation reached the asymptotic values after 120 minutes, presumably due 
to the equilibrium between the uptake and efflux and/or release. Hence, ciprofloxacin 
accumulation was assessed at 120 minutes in the subsequent experiments. This concentration-
dependent accumulation for CPFX and Lipo-CPFX is described in more detail below.  
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Figure 3.3 Time-course accumulation of ciprofloxacin into the NR8383 cells at 37 
o
C following 
application of (a) CPFX and (b) Lipo-CPFX at 10 (left pane) and 200 µg/ml (right pane). Data: 
mean ± SD (N=4). 
(a) CPFX 
(b) Lipo-CPFX 
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3.3.3 Concentration-dependent accumulation for CPFX and Lipo-CPFX into the NR8383  
cells at 37 
o
C                    
 
Figure 3.4 shows the concentration-dependent accumulation of ciprofloxacin for CPFX and 
Lipo-CPFX into the NR8383 cells (passage 9-10) at 37 
o
C, assessed as the asymptotic values at 
120 minutes. For both CPFX and Lipo-CPFX, the accumulation was generally increased with 
increasing the concentration in the range of 10-200 µg/ml. However, the profile for CPFX 
appeared to be non-linear, where the accumulation was proportionally increased with the 
concentration at ≤ 80 µg/ml, and became deviated to the values less than proportional to the 
concentration at ≥ 80 µg/ml. Indeed, at 180 and 200 g/ml (i.e., two of the highest tested 
concentrations), the ciprofloxacin masses accumulated were 1186 ± 91 and 1086 ± 154 ng/10
6
 
cells, respectively, which were insignificantly different (p > 0.05). While this may have 
demonstrated saturation in the accumulation, such a deduction remains inconclusive without 
further supporting data. In contrast, the profile for Lipo-CPFX appeared to be linear, except at 
200 g/ml, at which the accumulation was greater than the value predicted from the linearity of 
the profile. Overall, Lipo-CPFX resulted in greater accumulation of ciprofloxacin into the 
NR8383 cells, compared to CPFX (two-way ANOVA, p < 0.05), while there was no significant 
difference in these values between Lipo-CPFX and CPFX at 10 and 20 µg/ml (p > 0.05).  
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Figure 3.4 Concentration-dependent accumulation of ciprofloxacin for CPFX and Lipo-CPFX 
into the NR8383 cells at 37 
o
C, assessed as the asymptotic values at 120 minutes. Data: mean ± 
SD (N=4). 
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3.3.4 Effects of NH4Cl on the accumulation of CPFX and Lipo-CPFX into the NR8383 cells 
 
Figure 3.5 shows the effects of 50 mM NH4Cl treatment on the time-course profiles of 
ciprofloxacin accumulation into the NR8383 cells (passage 13-15) at 37 
o
C following application 
of (a) CPFX and (b) Lipo-CPFX at 200 g/ml. This experiment was to test the effect of an 
elevated pH inside the cell cytosol and liposomes on accumulation, as ciprofloxacin’s cellular 
disposition and/or release from the liposomes may be altered by this pH elevation. As shown in 
Figure 3.5 (a), the accumulation for CPFX was overall unaffected by 50 mM NH4Cl, as the 
accumulation profiles were overlaid during 240 minutes (two-way ANOVA, p > 0.05) except at 
30 minutes. In contrast, 50 mM NH4Cl significantly reduced the accumulation for Lipo-CPFX in 
the first 60 minutes as shown in Figure 3.5 (b), resulting in the apparent first-order profile similar 
to that for CPFX (two-way ANOVA, p < 0.05). Indeed, as shown in Figure 3.6, the profiles for 
CPFX and Lipo-CPFX in the presence of NH4Cl were statistically indistinguishable (two-way 
ANOVA, p > 0.05). These data implied that an elevated pH by NH4Cl, caused ciprofloxacin 
release from the liposomes prior to the cellular uptake, presumably due to reduced acid trap of 
ciprofloxacin within the liposomes. If so, this, in turn, would suggest that, under the control 
condition, i.e., in the absence of NH4Cl or at a physiologically-relevant neutral pH, Lipo-CPFX 
was taken up by the NR8383 cells as the liposomes, enabling greater uptake, as seen in the 
profiles at ≤ 30 minutes in Figures 3.5 (b). Note that the addition of NH4Cl did not significantly 
change the pH of the extracellular incubation media. 
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Figure 3.5 Time-course accumulation of ciprofloxacin into the NR8383 cells at 37 
o
C following 
application of (a) CPFX and (b) Lipo-CPFX at 200 µg/ml in the absence (control) or presence of 
50 mM NH4Cl. Data : mean ± SD (N=4), * two-way ANOVA, p < 0.05 .  
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Figure 3.6 Accumulation profiles for CPFX and Lipo-CPFX at 200 g/ml in the presence of 50 
mM NH4Cl at 37 
o
C. Data : mean ± SD (N=4). 
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3.3.5 Ciprofloxacin efflux and/or release from the NR8383 cells upon CPFX and Lipo-
CPFX accumulation  
 
Figure 3.7 shows the time-course profiles of ciprofloxacin efflux and/or release from the 
NR8383 cells (passage 12) at 37 
o
C following 2 hour accumulation for CPFX and Lipo-CPFX at 
10 g/ml. At 10 g/ml, the ciprofloxacin masses accumulated by 2 hours were consistent at ~100 
ng in 10
6
 cells for both CPFX and Lipo-CPFX, as shown in Figures 3.3. Thus, the intracellular 
ciprofloxacin concentrations at the start of efflux and/or release studies (i.e., time 0 on Figure 
3.7) were also in theory consistent. Ciprofloxacin efflux and/or release was rapid and kinetically 
apparent first-order for both formulations. Most notably, the profiles for CPFX and Lipo-CPFX 
were effectively overlaid (two-way ANOVA, p > 0.05), which suggested the comparable kinetics 
and mechanisms for this efflux and/or release, despite different uptake mechanisms suggested 
above. In addition, the efflux and/or release of ciprofloxacin for CPFX and Lipo-CPFX from the 
NR8383 cells were almost complete (89.1 and 89.3 % of ciprofloxacin efflux at 240 minutes, 
respectively). Likewise, the % efflux and/or release profiles of ciprofloxacin from the NR8383 
cells following accumulation of CPFX and Lipo-CPFX at 200 µg/ml were not significantly 
different (two-way ANOVA, p > 0.05), as shown in Figure 3.8. Note that because of a difference 
in the ciprofloxacin mass accumulated at 200 µg/ml, the Y-axis in Figure 3.8 is expressed as the 
% of the efflux and/or release profiles.    
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Figure 3.7 Cumulative ciprofloxacin mass effluxed and/or released from the NR8383 cells at 37 
o
C after 2 hour accumulation of CPFX and Lipo-CPFX at 10 µg/ml. Data : mean ± SD (N=3-4), 
two way ANOVA, p > 0.05 
 
 
 
 
 
 
0 
20 
40 
60 
80 
100 
120 
0 60 120 180 240 
C
ip
ro
fl
o
xa
ci
n
 m
as
s 
e
ff
lu
xe
d
/r
e
le
as
e
d
 f
ro
m
 1
0
6  
N
R
8
3
8
3
 c
e
lls
 (
n
g)
 
Time (minutes) 
CPFX 
Lipo-CPFX 
 
 
39 
 
 
 
Figure 3.8 Cumulative % ciprofloxacin mass effluxed and/or released from the NR8383 cells at 
37 
o
C after 2 hour accumulation of CPFX and Lipo-CPFX at 200 µg/ml. Data : mean ± SD 
(N=3-4), two way ANOVA, p > 0.05 
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3.3.6 Effects of 4 
o
C on ciprofloxacin efflux and/or release from NR8383 cells following 
CPFX and Lipo-CPFX accumulation 
 
Figure 3.9 shows the ciprofloxacin mass effluxed and/or released from the NR8383 cells 
(passage 12) at 37 and 4 
o
C following 2 hour accumulation of (a) CPFX and (b) Lipo-CPFX at 
10 µg/ml at 37 
o
C. For both CPFX and Lipo-CPFX, the reduced temperature resulted in a 
reduction of the ciprofloxacin efflux and/or release from the NR8383 cells. At 240 minutes of the 
asymptotic period, the ciprofloxacin masses effluxed and/or released were only 70.2 ± 11.6 % 
for CPFX and 64.9 ± 5.9 % for Lipo-CPFX at 4 
o
C, compared to near 90 % at 37 
o
C (as 
described in section 3.3.5). These suggested that the ciprofloxacin efflux and/or release was a 
mixture of temperature-dependent and –independent mechanisms, yet kinetically consistent 
between CPFX and Lipo-CPFX.  
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Figure 3.9 (a) Effects of 4 
o
C on ciprofloxacin efflux from the NR8383 cells following 2 hour 
accumulation for CPFX at 10 µg/ml. Data : mean ± SD (N=2-4). (* p<0.05) 
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Figure 3.9 (b) Effects of 4 
o
C on ciprofloxacin efflux from the NR8383 cells following 2 hour 
accumulation for Lipo-CPFX at 10 µg/ml. Data : mean ± SD (N=4). (* p<0.05) 
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3.4. Discussion 
 
Ciprofloxacin accumulation for CPFX and Lipo-CPFX into the NR8383 cells appeared to be cell 
passage-dependent and a net result of uptake and efflux and/or release. It has been known that 
the cell passage can be critical in the continuous cell line culture in vitro, as the morphology, 
growth rate, and protein expression can be different upon passage [ATCC, technical bulletin, 
2007]. For instance, Yu et al (1997) reported a difference in the transport activity between high- 
and low-passage Caco-2 cell monolayers, where the higher passage cell monolayers (P39-108) 
showed decreased transport of phenylalanine, an amino acid transporter substrate, compared to 
the lower passage monolayers (P28-36), attributed to a decreased amino acid transporter 
expression at the higher cell passage. In the same study, it was also shown that the transport of 
mannitol via paracellular diffusion was slower for the higher passage monolayers than the lower 
passage monolayers, suggesting a reduced cell monolayer’s integrity with increasing the passage. 
Therefore, it was necessary to assess such cell passage dependence of ciprofloxacin 
accumulation in the NR8383 cells in this present study. As shown in Figure 3.1, the cells at the 
higher passage (P15) showed significantly greater ciprofloxacin accumulation than the cells at 
the lower passage (P10), which could be a result of increased uptake and/or decreased efflux 
during the culture and passage which remains to be investigated. Regardless of the mechanisms, 
however, this demanded the use of passage-matched cells to compare the kinetics and 
mechanisms of ciprofloxacin accumulation for CPFX and Lipo-CPFX in this study.  
The ciprofloxacin accumulation for CPFX and Lipo-CPFX into the NR8383 cells was seen to be 
concentration-dependent, and Lipo-CPFX overall showed greater accumulation than CPFX, as 
shown in Figure 3.4. This suggested that the kinetics and mechanisms of accumulation into the 
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NR8383 cells are different. Further analysis was attempted to the concentration-dependent 
accumulation profiles for CPFX and Lipo-CPFX. While the CPFX concentration dependent 
profile appeared clearly linear in the tested concentration range of 10-80 µg/ml, there was also 
saturation possibly seen at the higher concentrations. Recognizing apparent saturation of 
accumulation for CPFX at 180 and 200 g/ml, the Michaelis-Menten-type kinetics were applied 
in curve-fitting, yielding a R
2
 value of 0.85. Coincidentally, however, the linear regression 
analysis also yielded a R
2
 value of 0.85, leaving this kinetic analysis inconclusive for CPFX in 
the present study. The accumulation data at > 200 g/ml would have produced a clearer profile 
for CPFX, yet was not possible due to the solubility limit at 200 g/ml in PBS.  
In the literature many transporter systems have been reported for ciprofloxacin. Hence, it is 
likely that the involvement of such transporters can affect the concentration dependent profile of 
CPFX. In this regard, Michot et al [2004] reported that CPFX accumulation into the J774 murine 
macrophages was also concentration-dependent, which appeared to be kinetically exponential 
without saturation, attributed to the contribution of efflux transporters, such as multidrug 
resistant proteins (MRPs) and P-glycoprotein (P-gP). Similarly, Park et al [2011] suggested the 
contribution of efflux transporters, such as P-gP, for CPFX in canine kidney cells. They showed 
that human P-gP over expressing canine kidney cells (MDCKI-MDR1) showed significantly 
higher ciprofloxacin transport, compared to the control cells (MDCKI). It was shown that the 
basolateral to apical (B-to-A) transport of ciprofloxacin in MDCKI-MDR1 cells was 
significantly higher than that in the control MDCKI cells. Further, the B-to-A: A-to-B 
ciprofloxacin transport ratio in the MDCKI-MDR1 was significantly reduced in the presence of 
known P-gP inhibitor verapamil, all suggesting ciprofloxacin as a substrate for the P-gP 
transporter. Indeed, as summarized in Table 3.1, several studies have also suggested efflux 
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transporters (e.g., P-gP and breast cancer resistant protein, BCRP) affecting CPFX transport in 
different cells, which was apparently highly cell type-specific. Nevertheless, it is clear that such 
efflux transporters would not cause saturation in the concentration-dependent accumulation 
profile for CPFX but uptake transporters. Because CPFX is a zwitterion at a physiological 
neutral pH, several studies have shown that CPFX can act as a substrate for organic cation and 
anion transporters (OCTs and OATs), as summarized in Table 3.1.  
Dautrey et al [1999] reported OCTs- and OATs-mediated transport of ciprofloxacin in rat 
intestinal models. They showed that cephalaxin and azlocillin, which are β-lactams and OAT 
and/or OCT substrates, significantly reduced the intestinal elimination of ciprofloxacin by 1.3 to 
2.0-fold suggesting the involvement of OCT and/or OAT mediated transport of ciprofloxacin. 
Another study by Cavet et al [1997] reported OATs-mediated transport of ciprofloxacin across 
the Caco-2 cell monolayers. They showed that net secretion of ciprofloxacin in the Caco-2 cells 
was inhibited by an OAT substrate - 4,4`-diisothiocyanosotilbene-2-2`-disulphonic acid (DIDS).  
Hence, ciprofloxacin has been indicated to be a substrate for both OCTs and OATs. In addition 
to the above mentioned uptake and efflux transporters, other active and saturable uptake 
processes like endocytosis can also mediate the uptake of CPFX, given the phagocytotic nature 
of the NR8383 cells. However, at present, whether such uptake transporters or endocytotic 
processes are involved in the accumulation of CPFX into the NR8383 cells remains unknown. It 
is still generally believed that CPFX uptake is via kinetically non-saturable diffusion, possibly 
along with facilitated diffusion via membrane carrier proteins. If so, the concentration-dependent 
accumulation profile for CPFX shown in Figure 3.4 would be regarded as the linear profile 
suggesting CPFX uptake likely via passive processes like diffusion.   
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Such a passive diffusion of ciprofloxacin has also been reported by Easmon et al [1985] with 
mouse peritoneal macrophages. They reported that the macrophages whose proteins were cross 
linked by treatment with 10 % formalin, still maintained an intracellular to extracellular 
ciprofloxacin concentration ratio (IC:EC ratio), equal to that seen with live cells, after 5 minutes, 
and caused a slightly greater IC:EC ratio after 30 minutes. It is reasoned that the formalin cross 
linking with the membrane uptake and efflux transporter proteins likely lead to compromised 
active transport process, allowing only passive process like diffusion to take place. In this regard, 
a possibility for the uptake of CPFX by the NR8383 cells via diffusion remained to be clarified 
with further mechanistic experiments.  
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Table 3.1 In vitro and in vivo studies suggesting the involvement of different transporters in 
ciprofloxacin uptake and/or transport 
 
Model  Ciprofloxacin 
dose/concentrati
on  
Results Conclusions Reference 
Murine J774 
macrophages 
17 µg/ml (51.3 
µM) 
Reduced efflux in the 
presence of a MRP 
inhibitor probenecid 
MRP mediated 
efflux  
Michot et 
al, 2004 
Bcrp1-MDCKII 
cells 
3314 µg/ml (10 
mM) 
Abolished transport by 
a BCRP inhibitor 
Ko143 
BCRP mediated 
transport  
Haslam et 
al, 2011 
Human intestinal 
epithelial Caco-2 
cells 
1657-3314 µg/ml 
(5-10 mM) 
Inhibited transport by 
an OAT substrate  
OAT but not P-gP 
mediated transport  
Cavet et 
al, 1997 
MRD- and P-gP-
MDCK cells 
8285-33140 
µg/ml (25-100 
mM) 
Bidirectional transport 
ratio greatly reduced 
by verapamil 
P-gP mediated 
transport  
Park et al, 
2011 
In vivo rat model 12.5 mg/kg 
intravenous dose 
Decreased intestinal 
clearance by OCT and 
OAT inhibitors 
OAT and OCT but 
not P-gP mediated 
transport  
Dautrey et 
al, 1999 
In vivo BCRP 
knockout mouse 
model 
10 mg/kg  oral 
dose 
2-fold increase in the 
plasma levels  
BCRP mediated 
transport  
Merino et 
al, 2006 
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In contrast to CPFX, Lipo-CPFX showed effectively a linear concentration-dependent 
accumulation profile without apparent saturation (Figure 3.4); linear regression was attempted, 
yielding a R
2
 value of 0.96. It was clear therefore that the kinetics and mechanisms of 
accumulation were different between CPFX and Lipo-CPFX, considering their different 
concentration dependent profiles. In this context, it was notable that under the NH4Cl treatment, 
the accumulation profile for Lipo-CPFX became overlaid with that for CPFX (Figure 3.6), 
without initial greater uptake seen in Figure 3.5 (b). This NH4Cl treatment has been often used in 
the literature as a means to elevate a pH value within the phospholipid bilayer systems, including 
cells and liposomes [Poteser et al, 2003]. Because Lipo-CPFX retains ciprofloxacin inside the 
liposomes due to a lower intra-liposomal pH causing formation of impermeable ionized species, 
such an elevated pH should form more net neutral molecules rather enabling leak-out from the 
liposomes. If so, the accumulation for Lipo-CPFX should be logically same as that for CPFX 
upon the NH4Cl treatment, like seen in Figure 3.6. This, in turn, suggested that, at a 
physiological pH, Lipo-CPFX was taken as liposomes, causing the initial rapid and greater 
uptake by 30 minutes (Figure 3.5 (b)). After all, Lipo-CPFX was a nano-particulate system and 
not a solution system and hence, the liposomes may have interacted with the NR8383 cells for 
uptake in a different fashion.  
The major processes that are involved in the uptake of the particulates like liposomes by the 
NR8383 cells are endocytosis and fusion mechanisms. Among the endocytotic processes, the 
primary mechanisms commonly expected for liposomes are phagocytosis, actin-mediated 
endocytosis, and clathrin-mediated endocytosis [Ruckert et al, 2003]. The actin and clathrin 
microfilaments constituting the NR8383’s cytoskeleton are involved in the uptake of liposomes 
via formation of membrane vesicles that engulf and transport the liposomes into the macrophage. 
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These endocytotic processes are commonly energy dependent and saturable active processes.  
Barratt et al [1986] reported that phagocytotic uptake of liposomes composed of phospholipid 
and cholesterol by rat alveolar macrophages was saturable at high liposome concentrations and 
energy dependent. Douglas et al [1999] showed that the rat alveolar macrophages incubated with 
anti-clathrin antibody encapsulated liposomes showed lower endocytotic activity, suggesting the 
role of clathrin mediated endocytosis in the uptake of liposomes. Ruckert et al (2003) reported 
that cytochalasin D, an inhibitor of actin polymerization, reduced the uptake of liposomes by 
alveolar type II cells by 55 %, suggesting the actin mediated endocytotic uptake of liposomes. 
Such actin and clathrin-mediated endocytotic process is an energy dependent process that can be 
expected to saturate at high concentrations or at low temperatures [Khalil et al, 2006].   
However, Lipo-CPFX exhibited proportional increase of ciprofloxacin accumulation into the 
NR8383 cells to concentration without saturation at 10-200 µg/ml. Such a linear and non-
saturable profile observed for Lipo-CPFX was not depictive of endocytotic uptake of the 
liposomes by the NR8383 cells, as such endocytotic uptake of liposomes generally is non-linear 
and saturable [Barrat et al, 1986]. This rather suggested that the uptake of Lipo-CPFX by the 
NR8383 cells energy independent and thus likely via non-endocytotic process like fusion. 
Evidence for such energy-independent uptake of liposomes by eukaryotic cells via a fusion 
process has already been reported in the literature. Marchini et al [2011] reported that DNA 
encapsulated liposomes termed “lipoplexes” were able to transfect mouse fibroblasts and 
Chinese hamster ovary cells even at a reduced temperature of 4 
o
C – a temperature which is 
known to shut down endocytotic processes. They thus attributed their internalization mechanism 
to other than endocytosis type of mechanisms like fusion. A similar result was also reported by 
Batzri et al, (1975), where the uptake of unilamellar phospholipid vesicles by Chinese hamster 
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V79 cells was found to be insensitive to energy metabolism inhibitors like sodium azide. 
Moreover, the uptake of the liposomes by the V79 cells was inhibited only by 25 % at 4 
o
C, 
compared to 37 
o
C. The authors thus attributed the internalization mechanisms seen in these 
cases to be non-endocytotic processes like fusion. Hence, it is likely that the Lipo-CPFX 
accumulated into the NR8383 cells via an energy independent and non-endocytotic process like 
fusion, given the linear accumulation profile for Lipo-CPFX. 
Overall, it was suggested that Lipo-CPFX enabled greater ciprofloxacin accumulation into the 
NR8383 cells due to different uptake mechanism compared to CPFX. Such greater ciprofloxacin 
accumulation for Lipo-CPFX was also reported in vivo by Chono et al (2008) where liposomal 
ciprofloxacin showed superior pharmacokinetics following pulmonary administration to rats. The 
authors reported that, at the same dose of 200 µg/kg, liposomal ciprofloxacin showed higher and 
sustained levels of intracellular ciprofloxacin in the alveolar macrophages compared to free 
ciprofloxacin. The liposomal ciprofloxacin was shown to sustain intracellular ciprofloxacin at 50 
µg/ml even after 24 hours of pulmonary administration, while the free ciprofloxacin level was 
not detected beyond 12 hours in the alveolar macrophage.  
In contrast to the different and overall greater uptake seen for Lipo-CPFX, the efflux and/or 
release profiles were overlaid for both CPFX and Lipo-CPFX, suggesting that the efflux and/or 
release was due to ciprofloxacin for both the formulations (Figures 3.7 and 3.8). This logically 
suggested that Lipo-CPFX taken by the cells released ciprofloxacin and/or was broken within the 
cells, followed by efflux and/or release as ciprofloxacin from the cells. Notably, this efflux 
and/or release were a result of temperature-dependent and -independent mechanisms (Figure 
3.8). It was seen that almost 90 % of the ciprofloxacin mass accumulated in the NR8383 cells 
was effluxed from the cells in 240 minutes for both CPFX and Lipo-CPFX at 37 
o
C, irrespective 
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of the drug concentrations at 10-200 µg/ml. Therefore, even with accumulation of higher 
amounts of ciprofloxacin, the efflux profiles were similar for both CPFX and Lipo-CPFX at 37 
o
C. The reduction of temperature to 4 
o
C resulted in the decreased rate and extent of 
ciprofloxacin efflux following accumulation of CPFX and Lipo-CPFX. This suggested that the 
efflux involves an energy dependent mechanism along with a passive process. Further, this 
reduction was also similar for both the formulations, suggesting that the active ciprofloxacin 
efflux mechanisms are likely the same for both the formulations. Hence it is likely that any of the 
commonly known efflux transporters like P-gP, MRP or BCRP as discussed earlier might be 
involved in this active/energy-dependent efflux of ciprofloxacin following CPFX and Lipo-
CPFX accumulation into the NR8383 cells. In this regard it is notable that an energy-dependent 
efflux for ciprofloxacin has been reported by Michot et al (2004) in the J774 macrophages that 
was inhibited by multi-drug resistance protein (MRP) inhibitors. Hence, further mechanistic 
experiments will be necessary to identify the efflux transporter(s) involved in the ciprofloxacin 
efflux following CPFX and Lipo-CPFX accumulation into the NR8383 cells.  
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3.5 Conclusion 
 
In this chapter, the ciprofloxacin accumulation for CPFX and Lipo-CPFX into the NR8383 cells 
was characterized in vitro with respect to cell passage-, kinetics-, and concentration-dependence. 
The accumulation was found to be greater for the higher passage cells compared to the lower 
passage cells. The kinetics of accumulation differed based on applied concentrations. Indeed, 
ciprofloxacin accumulation for both CPFX and Lipo-CPFX was a net result of uptake and efflux 
and/or release. As a result, Lipo-CPFX overall enabled greater ciprofloxacin accumulation into 
the NR8383 cells than CPFX (Figure 3.3), which could be an advantage of Lipo-CPFX in 
targeted delivery of ciprofloxacin into the alveolar macrophages.  
The greater ciprofloxacin accumulation enabled by Lipo-CPFX was likely due to its uptake 
mechanism differing from that of CPFX, as the efflux and/or release profiles were kinetically 
same for both the formulations. Lipo-CPFX uptake by the NR8383 cells appeared to be via a 
non-endocytotic uptake mechanisms, whereas CPFX uptake appeared to be via an endocytotic or 
passive uptake process like diffusion. Overall, uptake and efflux and/or release for the two 
formulations were rapid. Specifically, the uptake appeared to be faster for Lipo-CPFX, compared 
to CPFX, whereas the efflux and/or release were kinetically same. The efflux for both CPFX and 
Lipo-CPFX was lowered partially and to similar extents due to temperature reduction indicating 
efflux to be a combination of active and passive processes. The overlaid efflux and/or release 
profiles for CPFX and Lipo-CPFX also suggested the break-down of Lipo-CPFX inside the 
NR8383 cells upon its uptake, thus releasing the encapsulated ciprofloxacin subject to efflux 
 
 
53 
 
and/or release. Hence, in chapter 4, the mechanisms for these uptake and efflux will be further 
explored using biochemical inhibitor approaches. 
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CHAPTER 4 
 
EXPLORING MECHANISMS OF CIPROFLOXACIN ACCUMULATION FOR CPFX 
AND LIPO-CPFX INTO THE NR8383 CELLS 
 
 
 
4.1 Introduction 
 
In the previous chapter, the kinetics of ciprofloxacin accumulation for CPFX and Lipo-CPFX 
into the NR8383 cells was characterized. However, the mechanisms involved in the uptake and 
efflux for these two formulations remains speculative. Hence, in this chapter, studies continue to 
explore the mechanisms involved in the accumulation for CPFX and Lipo-CPFX into the 
NR8383 cells under experimental perturbations of certain transport processes. The effects of a 
reduced temperature and ATP depleting agents on the accumulation were first studied to identify 
active cellular energy-dependent processes in the accumulation for CPFX and Lipo-CPFX. 
Subsequently, inhibitors of efflux transporters and endocytosis were used to examine their 
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effects on the accumulation for CPFX and Lipo-CPFX. The accumulation was also assessed 
following cell treatment with formalin and in the presence of empty liposomes.  
 
4.2 Materials and methods 
 
4.2.1 Drugs 
 
Lipo-CPFX (50 mg/ml; Aradigm Corporation) was diluted to designated concentrations with 0.1 
mM PBS (pH 7.4) prior to each experiment. Ciprofloxacin hydrochloride (MP Biomedicals, 
Solon, OH) was dissolved in PBS to obtain designated concentrations of CPFX solution.  
 
4.2.2 Inhibitors and transport modifiers  
 
Table 4.1 lists inhibitors and transport modifiers used in this study alongside their intended 
inhibitory and/or modulatory activities, concentrations used in the literature, as adapted for this 
study, suppliers and the literature.  
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Table 4.1: Inhibitors and transport modifiers used in the accumulation for CPFX and Lipo-
CPFX into the NR8383 cells 
 
Inhibitor / Modifier Intended activity Tested 
concentration 
Supplier Reference 
Deoxyglucose ATP depletion 50 mM Acros 
Organics 
Michot et al, 
2004 
Sodium azide ATP depletion 5 mM Fisher Michot et al, 
2004 
Probenecid MRP inhibition 5 mM Sigma Michot et al, 
2004 
Verapamil P-gP inhibition 100 µM Sigma Michot et al, 
2004 
Cytochalasin D Actin mediated 
endocytosis 
19.7 µM Sigma Ruckert et 
al, 2003 
Amantadine 
hydrochloride 
Clathrin mediated 
endocytosis 
26.6 mM Sigma Ruckert et 
al, 2003 
Chlorpromazine Clathrin mediated 
endocytosis 
14 µM Sigma Rejman et 
al, 2005 
Formalin Membrane protein cross-
link; plasma membrane 
hardening 
10 % w/v Fisher 
Scientific 
Easmon et 
al, 1985 
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4.2.3 Ciprofloxacin accumulation for CPFX and Lipo-CPFX into the NR8383 cells under 
various transport perturbations  
 
Ciprofloxacin accumulation into the NR8383 cells were assessed at 2 hours of incubation with 
CPFX or Lipo-CPFX, as described in Chapter 3 (Sections 3.2.4), with or without the following 
experimental transport perturbations:  
 
4.2.3 (a) Accumulation at 4 
o
C 
 
The reduced temperature at 4 
o
C has been often used to make cellular energy unavailable for 
active energy-dependent processes, while also causing decreased membrane fluidity possibly 
affecting diffusion. The experimental procedure differed from that at 37 
o
C described in Chapter 
3 (Section 3.2.4) only in the use of 4 
o
C during the accumulation studies.  
 
4.2.3 (b) Accumulation in the presence of ATP depleting reagents 
 
Deoxyglucose and sodium azide were used as ATP-depleting reagents to assess the involvement 
of cellular ATP hydrolysis energy in the uptake and/or efflux. The NR8383 cells were first pre-
incubated with 0.2 ml of 250 mM deoxyglucose or 25 mM sodium azide for 10 minutes to ensure 
sufficient ATP depletion [Michot et al, 2004]. Subsequently, 0.8 ml CPFX or Lipo-CPFX was 
added and incubated at 37 
o
C to determine ciprofloxacin accumulation for 2 hours in the 
presence of 50 mM deoxyglucose or 5 mM sodium azide.  
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4.2.3 (c) Accumulation in the presence of probenecid and verapamil 
 
Probenecid and verapamil were best known as inhibitors of multidrug resistance proteins (MRPs) 
and P-glycoprotein (PgP), respectively. Note however that verapamil has been also shown to 
inhibit MRPs at high concentrations and decrease intracellular pH [Bai et al, 2004; Hamilton et 
al, 1993]. The NR8383 cells were first pre-incubated with 0.2 ml of 25 mM probenecid and 0.5 
mM verapamil for 10 minutes, to ensure sufficient MRP/PgP inhibition [Michot et al, 2004]. 
Subsequently, 0.8 ml CPFX or Lipo-CPFX was added and incubated at 37 
o
C to determine 
ciprofloxacin accumulation for 2 hours in the presence of 5 mM probenecid and 0.1 mM 
verapamil. 
 
4.2.3 (d) Accumulation in the presence of cytochalasin D, chlorpromazine and amantadine  
 
Cytochalasin D was used as an inhibitor of actin-mediated endocytosis [Ruckert et al, 2003], 
while chlorpromazine and amantadine hydrochloride were as inhibitors of clathrin-mediated 
endocytosis [Ruckert et al, 2011]. The NR8383 cells were first pre-incubated with 0.2 ml of 50 
µg/ml cytochalasin D, 25 µg/ml chlorpromazine or 25 mg/ml amantadine hydrochloride for 10 
minutes. Subsequently, 0.8 ml CPFX or Lipo-CPFX was added and incubated at 37 
o
C to 
determine ciprofloxacin accumulation for 2 hours in the presence of 10 µg/ml cytochalasin D, 5 
µg/ml chlorpromazine or 5 mg/ml amantadine hydrochloride. 
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4.2.3 (e) Accumulation following 10 % formalin treatment  
 
Formalin treatment was used to crosslink and deactivate membrane proteins, while maintaining 
the plasma membrane intact [Hayat, 2000]. It was therefore expected to impair cell membrane 
protein-mediated transport of uptake and efflux. The NR8383 cells were pre-incubated with 10 
% formalin at 37 
o
C for 30 minutes. Subsequently, the formalin solution was replaced with 
CPFX or Lipo-CPFX for 2 hour accumulation at 37 
o
C.  
 
4.2.3 (f) Accumulation in the presence of empty liposomes 
 
The empty liposomes were used as a possible modulator of liposome-mediated transport 
processes and/or plasma membrane fluidity of the NR8383 cells. The NR8383 cells were 
incubated with equal volumes of CPFX solution or Lipo-CPFX suspension and the empty 
liposome suspension (1:1 volume ratio) at 37 
o
C for 2 hours to determine the ciprofloxacin 
accumulation.  
 
4.2.4 Sample, data and statistical analysis 
 
The sample, data and statistical analysis were carried out in a way similar to that described in 
sections 3.2.6 and 3.2.7 of Chapter 3.  
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4.3 Results and Discussion 
 
4.3.1 Effects of 4 oC and ATP depleting agents on ciprofloxacin accumulation for CPFX 
and Lipo-CPFX into the NR8383 cells  
 
Figure 4.1 shows the ciprofloxacin accumulation for (a) CPFX and (b) Lipo-CPFX into the 
NR8383 cells at 10-200 g/ml for 2 hours at 4 oC, compared to that at 37 oC. The data at 37 oC 
are those shown in Figure 3.3 (Chapter 3). Overall, the reduced temperature at 4 
o
C resulted in 
greater accumulation for both CPFX and Lipo-CPFX into the NR8383 cells, compared to 37 
o
C. 
However, the temperature effects on the accumulation were in lesser extents for Lipo-CPFX, 
compared to CPFX, as the ciprofloxacin accumulation was increased at 4 
o
C by an averaged 2.0- 
and 1.4-fold for CPFX and Lipo-CPFX, respectively. This increased accumulation at 4 
o
C was 
consistent with the decreased efflux at 4 
o
C shown in the previous chapter as a partially 
temperature-dependent mechanism (Figure 3.8). Accordingly, Tables 4.2 (a) and (b) summarize 
the 2 hour ciprofloxacin accumulation and fold-increase for CPFX and Lipo-CPFX at 140 µg/ml 
at 4 
o
C and under ATP depletion with 50 mM deoxyglucose and 5 mM sodium azide, compared 
to the control condition. It was notable that the magnitudes of fold-increase in the accumulation 
were statistically equivalent under these perturbations, i.e., 2.1-2.3-folds for CPFX and 1.2-1.8-
folds for Lipo-CPFX compared to the controls (one-way ANOVA, p > 0.05). It was likely 
therefore that the decreased temperature effects resulted from the ATP depletion, which 
supported that the efflux for both CPFX and Lipo-CPFX was a cell energy-dependent process.  
Deoxyglucose was used as an inhibitor of cellular glycolysis and sodium azide was as an 
inhibitor of cellular energy derived from respiration [Leeper-Woodford et al, 1992; Trinchieri et 
 
 
61 
 
al, 1975; Zha et al, 1998]. The apparent absence of decreased uptake by the reduced temperature 
and in the presence of ATP depleting agents endorsed energy-independent mechanisms for both 
CPFX and Lipo-CPFX uptake into the NR8383 cells. For CPFX, passive uptake has been 
suggested in different macrophages. Easmon et al [1885] advocated passive diffusion, as both 
live and dead mouse peritoneal macrophages enabled comparable ciprofloxacin accumulation at 
37 
o
C. In human monocyte THP-1 cells, Hara et al [2000] reported ciprofloxacin accumulation 
linearly proportional to concentration and thus non-saturable, unlike active mechanisms. 
Meanwhile, the literature has been mixed with respect to liposome uptake mechanisms into the 
macrophages. Liposomes have been shown to undergo endocytosis using cellular ATP energy 
and/or lipid fusion without the use of cellular ATP energy [Ostro, 1983, Silverstein et al, 1977 & 
Batzri et al, 1975]. At 4 
o
C, liposomes were shown to fuse with the plasma membrane of amoeba 
[Batzri et al, 1975] and enabled transfection of the encapsulated DNA in mouse fibroblastic cells 
[Marchini et al, 2011]. Hence, the only slightly higher accumulation for Lipo-CPFX at 4 
o
C, 
compared to at 37 
o
C, likely implies their uptake via energy-independent mechanisms like lipid 
fusion by the NR8383 cells. The slightly higher accumulation seen for Lipo-CPFX is likely to be 
due to the inhibition of an active/energy dependent efflux of ciprofloxacin as discussed in section 
3.3.6. 
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Figure 4.1 Ciprofloxacin accumulation for (a) CPFX and (b) Lipo-CPFX into the NR8383 cells 
at 10-200 g/ml for 2 hours at 4 oC, compared to that at 37 oC. Data : mean±SD (N=4). 
(b) 
(a) 
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4.3.2 Effects of probenecid and verapamil on ciprofloxacin accumulation for CPFX and 
Lipo-CPFX into the NR8383 cells at 37 
o
C 
 
In order to identify the efflux mechanisms suggested from the increased accumulation for CPFX 
and Lipo-CPFX into the NR8383 cells under the ATP depletion, probenecid and verapamil were 
used to inhibit MRPs and PgP, respectively [Michot et al, 2004]. Table 4.2 summarizes the 
effects of such efflux inhibitors on the 2 hour ciprofloxacin accumulation for (a) CPFX and (b) 
Lipo-CPFX at 140 g/ml. Probenecid at 5 mM was shown to increase ciprofloxacin 
accumulation by 2.2±0.2- and 1.5±0.2-fold, respectively. As these magnitudes of fold-increase 
were consistent with those at 4 
o
C and under the ATP depletion (Table 4.2), it was highly likely 
that probenecid-sensitive and thus MRPs-mediated effluxes were involved in the accumulation 
of ciprofloxacin for both CPFX and Lipo-CPFX. Indeed, the MRPs-mediated efflux has been 
reported for CPFX in the J774 macrophages [Tulkens et al, 2004].  
Probenecid at 10 mM was shown to increase the accumulation of ciprofloxacin by ~2.8-fold, 
which was primarily originated from 7.4-fold reduced efflux, while leaving the uptake unaltered 
[Tulkens et al, 2004]. Nevertheless, it requires caution to conclude this MRPs-mediated efflux, 
as probenecid is now also known to be a substrate for organic anion transporters (OATs). 
Steinberg et al (1987) reported probenecid-sensitive OAT-mediated transport in the J774 
macrophages, which extrudes OAT substrates, such as Lucifer yellow, an anionic and membrane 
impermeant fluorescent dye, outside of the cells. Likewise, probenecid increased the cellular 
accumulation of a different fluoroquinolone, norfloxacin, into the J774 macrophages by 3- to 4-
fold, which was primarily due to ~2-fold reduced efflux via OATs [Cao et al, 1992]. While such 
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OAT expression has not yet been confirmed in the NR8383 cells, this could be the efflux 
mechanisms for CPFX and Lipo-CPFX.   
By contrast, verapamil at 50 µM used as a Pgp inhibitor also significantly increased the 
accumulation for CPFX and Lipo-CPFX by 2.5±0.5- and 3.3±0.3-folds, respectively (Table 4.2). 
While this could have simply suggested the involvement of Pgp-mediated efflux, the greater 
folds-increase by verapamil, compared to those seen at 4 
o
C, under the ATP depletion and by 
probenecid should be questioned whether the verapamil effects were exclusively due to 
inhibition of Pgp-mediated efflux. In fact, in the J774 macrophages, the involvement of Pgp-
mediated efflux has been suggested to be minimal for CPFX [Tulken et al, 2004]. In addition, 
Pgp expression and function have been reported to be absent or low in primary cultured human 
macrophages, i.e., blood circulating macrophages [Moreau et al, 2011]. These fell in line with a 
possible argument that the verapamil’s enhancing effect on the accumulation for CPFX and 
Lipo-CPFX into the NR8383 cells is less likely due to inhibition of Pgp efflux. In this context, 
verapamil has been shown to inhibit organic cation transporters (OCTs) [Shugarts et al, 2009, 
FDA table of substrates, 2011]. However, if so, the magnitudes of fold-increase should have 
remained comparable to those seen at 4 
o
C, under the ATP depletion and by probenecid, and 
therefore, this was unlikely the case. Interestingly, it has also been reported that verapamil can 
inhibit the MRPs. Bai et al (2004) have reported that the efflux of bimane-glutathione (bimane-
GS, a MRP4 substrate) was significantly inhibited by 25 µM verapamil in MRP4 over expressing 
Hep G2 cells. Thus verapamil has been reported to affect both anionic and cationic transporter 
systems. Such a “bisubstrate” activity for verapamil has also been promoted by Ullrich et al 
(1993) owing to the presence of both an electronegative methoxy (-OCH3) and electropositive 
amino (NH2) in its structure. Hence, the increased accumulation of CPFX and Lipo-CPFX seen 
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in the presence of verapamil could have been due to its inhibitory activity on MRP(s) in the 
NR8383. 
Moreover, verapamil has also been reported to lower the intracellular pH in colon carcinoma cell 
lines [Hamilton et al, 1993]. If so, this may have caused increased accumulation for CPFX and 
Lipo-CPFX by virtue of increased acid trap of ciprofloxacin within the cells (as explained in 
section 1.8). Finally, verapamil also has been reported to increase the fluidity and permeability of 
the plasma membrane, thereby increasing the accumulation of drugs. Drori et al (1995), have 
reported that in the presence of 10 µM verapamil, there was a 3-4-fold increase in the influx rate 
and 11-17-fold increase in the “cell-associated” levels of taxol (a Pgp substrate) in Pgp lacking 
Chinese hamster ovary cells. Thus, it was shown that in cells that lack Pgp, the effect of 
verapamil to increase the accumulation of taxol, was unlikely to be due to Pgp efflux inhibition. 
Thus the increased accumulation of taxol seen in the presence of verapamil was attributed to 
increased membrane fluidity by verapamil. It is believed that owing to its lipophilic nature and 
positive charge, verapamil can accumulate into the negatively charged plasma membrane lipids; 
and that this can weaken the bonding forces between the adjacent lipids as a result of the steric 
effects from the isopropyl side chains in verapamil. Such an interaction of verapamil with the 
plasma membrane lipids is believed to increase the fluidity of the plasma membrane. Hence the 
2.5-and 3.5-fold higher accumulation for CPFX and Lipo-CPFX in the NR8383 cells seen in the 
presence of verapamil, was also speculative of increased plasma membrane fluidity in the 
NR8383 cells.  
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4.3.3 Effects of inhibitors of endocytosis on ciprofloxacin accumulation for CPFX and Lipo-
CPFX into the NR8383 cells at 37 
o
C 
Following accumulation studies with inhibitors of selected membrane transporters, the 
accumulation of CPFX and Lipo-CPFX was also studied in the presence of selected endocytosis 
inhibitors. Given cell energy-independent uptake as suggested in the accumulation studies with 
ATP depleting agents, it was unlikely that these inhibitors would affect the accumulation as 
endocytosis is known to be ATP dependent. Nevertheless, surprisingly it was seen that the 
accumulation of CPFX and Lipo-CPFX was increased by 2.4 – 4.4 and 1.2 – 2.1-fold 
respectively by these endocytosis inhibitors as shown in Table 4.2.  
In the presence of 10 µg/ml cytochalasin, it was seen that the accumulation of CPFX and Lipo-
CPFX was significantly increased. Cytochalasin is known to be an inhibitor of actin-mediated 
endocytosis [Ruckert et al, 2002], thus the increase in CPFX and Lipo-CPFX accumulation 
suggested a non-endocytotic uptake of the two formulations by the NR8383 cells. It therefore 
appeared that cytochalasin likely caused other cellular perturbations that caused the increase in 
CPFX and Lipo-CPFX accumulation. In this regard, it is to be noted that the membrane 
transporters that could mediate efflux of ciprofloxacin from the NR8383 cells are physically 
linked to the cytoskeleton of the cell. The proper functioning of the membrane transporters 
therefore depends on the integrity of the cell’s cytoskeleton. It has been reported by Hummel et 
al (2011) that the disruption of actin microfilaments in murine neuroblastoma cells (Neura cells, 
that endogenously express MRP1) and hamster BHK-cells (BHK-MRP1) stably expressing 
human MRP1, by 10 µg/ml cytochalasin treatment resulted in the increased retention of 5-
carboxyfluorescein diacetate (CFDA, a known MRP1 substrate). Hence cytochalasin’s effect of 
disruption of actin microfilaments that make up the cytoskeleton of the NR8383 cells is likely to 
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have affected the MRP-like transporter(s) mediated efflux of CPFX and Lipo-CPFX leading to 
increase in their accumulation.  
The application of 5 µg/ml chlorpromazine, which is known to be an inhibitor of clathrin 
mediated endocytosis [Rejman et al, 2005], also significantly increased the accumulation of 
CPFX and Lipo-CPFX by 2.4±0.3 and 1.6±0.5-fold respectively. Again, this suggested a non-
endocytotic uptake for CPFX and Lipo-CPFX by the NR8383 cells similar to the results seen 
with cytochalasin. The increase in accumulation seen in the presence of chlorpromazine was 
therefore suspected to be due to cellular perturbations other than inhibition of endocytosis. In this 
regard, it is interesting to note that chlorpromazine has been indicated as a substrate for MRPs 
[Tarnay et al, 2007]. Further, in the study by Naidu et al (2002), it has been reported that 
chlorpromazine resulted in decreased glutathione (GSH) levels in the forebrains of rats when 
administered intraperitoneally at a dose of 5 mg/kg. Thus it is likely that chlorpromazine could 
lead to decreased levels of GSH in the NR8383 cells, which can reduce the MRP mediated efflux 
since MRP(s) are known to require GSH for their activity [You et al, 2007]. This could have then 
increased the accumulation of CPFX and Lipo-CPFX in the NR8383 cells.  
A similar increase in CPFX and Lipo-CPFX accumulation into the NR8383 cells was also 
observed in the presence of 5 mg/ml amantadine, which is also known to be an inhibitor of 
clathrin mediated endocytosis [Moulakakis et al, 2009]. Hence, it was suggested that the 
accumulation of CPFX and Lipo-CPFX into the NR8383 cells was unlikely via clathrin mediated 
endocytosis. Therefore, it is likely that treatment with amantadine resulted in other cellular 
perturbations that might have increased the accumulation of CPFX and Lipo-CPFX. In this 
regard, it is to be noted that amantadine is known to be a substrate for OCTs [Ishiguro et al, 
2004; FDA table of substrates, 2011]. Given the zwitter ionic nature of ciprofloxacin, the 
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increased accumulation for CPFX and Lipo-CPFX was speculative of an amantadine inhibitable 
OCT mediated efflux mechanism of ciprofloxacin in the NR8383 cells. Such an argument also 
falls in line with the verapamil inhibitable OCT mediated efflux mechanism speculated for 
CPFX and Lipo-CPFX as discussed earlier. Apart from OCT inhibition, amantadine has also 
been reported to increase the permeability of the cell plasma membrane similar to verapamil’s 
case [Tverdislov et al, 1986]. In the study by Tverdislov et al (1986), it has been reported that 
treatment of human erythrocytes with 2-5 mM amantadine, resulted in an increase in membrane 
permeability. It is believed that amantadine is able to increase the spacing between the lipid 
molecules in the plasma membrane that can increase the membrane permeability [Tverdislov et 
al, 1986]. Hence such membrane permeability altering effects of amantadine are suspected to be 
involved in the increased accumulation of CPFX and Lipo-CPFX into the NR8383 cells.  
Hence, overall, it was seen that in the presence of all the tested endocytosis inhibitors, there was 
an increase in CPFX and Lipo-CPFX accumulation which suggested a non-endocytotic uptake of 
these two formulations by the NR8383 cells. Specifically for Lipo-CPFX, it is likely that its 
uptake is via a fusion process which was also consistent with the non-energy dependent 
accumulation seen for Lipo-CPFX in sections 4.3.1 and 4.3.2. It is speculated at this point that 
the tested endocytosis inhibitors interfere with the integrity of the NR8383’s plasma membrane 
and alter the efflux activity of the membrane transporter(s) that are likely to be involved in CPFX 
and Lipo-CPFX efflux. Further, it was noted that the effects of probenecid, verapamil, 
cytochalasin and chlorpromazine were consistent with a MRP-like transporter(s) mediated efflux 
being inhibited by these inhibitors leading to an increased CPFX and Lipo-CPFX accumulation. 
This was also in line with the results of Tulkens et al (2004) who have reported an increase in the 
accumulation of ciprofloxacin in the J774 macrophages in the presence of probenecid and 
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MK571 which are preferential MRP inhibitors. In this sense, our data was in more agreement 
with a MRP-like transporter(s) mediated efflux process for CPFX and Lipo-CPFX in the 
NR8383 cells. 
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Table 4.2 (a) Effects of reduced temperature and inhibitors on the accumulation of CPFX at 140 
g/ml into the NR8383 cells at 37 oC in 2 hours (data: Mean± SD, N=4, * Dunnet’s post-hoc test 
p<0.05) 
 Ciprofloxacin 
mass accumulated 
(ng per 10
6
 cells) 
Fold 
increase 
 Control 707.2 ± 114.9 - 
+ 4 
o
C 1408.3 ± 405.9*  2.1 ± 0.8  
+ 50 mM 
Deoxyglucose 
1880.4 ± 493.2* 2.5 ± 0.9 
+ 5 mM 
Sodium azide 
1435.3 ± 103.5* 2.1 ± 0.4 
+ 5 mM 
Probenecid 
1451.8 ± 210.1* 2.1 ± 0.3  
+ 100 µM 
Verapamil 
2107.0 ± 559.1* 3.1 ± 1.2 
+ 25 µg/ml 
Chlorpromazine 
1732.7 ± 204.9* 2.5 ±0.7 
+ 10 µg/ml 
Cytochalasin D 
3093.7 ± 79.0* 4.5 ± 0.8 
+ 5 mg/ml 
Amantadine 
hydrochloride 
2568.6 ± 461.9* 3.7 ± 0.5 
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Table 4.2 (b) Effects of reduced temperature and inhibitors on the accumulation of Lipo-CPFX 
at 140 g/ml into the NR8383 cells at 37 oC in 2 hours (data: Mean± SD, N=4, * Dunnet’s post-
hoc test p<0.05) 
 Ciprofloxacin 
mass accumulated 
(ng per 10
6
 cells) 
Fold 
increase 
Control 1790.9 ± 90.9 - 
+ 4 
o
C 2054.5 ± 172.9 1.2 ± 0.1  
+ 50 mM 
Deoxyglucose 
3164.7 ± 288.9* 1.8 ± 0.2  
+ 5 mM 
Sodium azide 
2708.6 ± 303.1* 1.5 ± 0.1  
+ 5 mM 
Probenecid 
2300.0 ± 408.5 1.3 ± 0.3  
+ 100 µM 
Verapamil 
6223.5 ± 474.2* 3.5 ± 0.4 
+ 25 µg/ml 
Chlorpromazine 
2735.8 ± 738.8* 1.6 ± 0.5 
+ 10 µg/ml 
Cytochalasin D 
3957.9 ± 348.3* 2.2 ± 0.3 
+ 5 mg/ml 
Amantadine 
hydrochloride 
2181.4 ± 106.3 1.2 ± 0.1 
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4.3.4 Effect of 10 % formalin pre-treatment on accumulation for CPFX and Lipo-CPFX 
into NR8383 cells at 37 
o
C 
 
Figure 4.2 shows the effects of 10 % formalin treatment on the 2 hour ciprofloxacin 
accumulation for (a) CPFX and (b) Lipo-CPFX at 200 g/ml into the NR8383 cells at 37 oC. 
Formalin was used as a membrane fixative reagent which crosslinks the membrane proteins and 
render them non-functional, while maintaining the plasma membrane intact allowing passive 
diffusion [Hayat, 2000]. The cross linking by formalin treatment occurs due to reaction of the 
formaldehyde of the formalin solution with the amino groups and peptide linkages of the 
membrane proteins leading to formation of methylene bridges between neighboring protein 
molecules thus cross-linking them with each other [Hayat, 2000]. Therefore, such a cross linking 
of formalin with the membrane proteins is believed to render the membrane proteins like MRP 
non-functional.  
It was seen that 10 % formalin pre-treatment significantly increased the accumulation for CPFX 
by 45.0 % (p < 0.05). While it was suggested from earlier studies that CPFX was subject to a 
MRP-like transporter(s) mediated efflux, the increase in accumulation of CPFX observed 
following the formalin pretreatment was suggestive of the impairment of this active/energy 
dependent efflux due to formalin cross linking with the MRP-like transporter(s). Since the active 
transport mechanisms are likely to be impaired by formalin pre-treatment, any uptake of CPFX 
by the NR8383 cells under these conditions could likely be via passive processes like diffusion.  
In contrast to CPFX, the accumulation of Lipo-CPFX into the NR8383 cells was significantly 
reduced by 18.6 % following formalin pre-treatment (p < 0.05). While it has been suggested 
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from earlier studies that Lipo-CPFX is also subject to MRP-like transporter(s) mediated efflux in 
the NR8383 cells, the formalin cross linking with the efflux transporter would be expected to 
increase the Lipo-CPFX accumulation. Thus the decrease in Lipo-CPFX accumulation suggested 
that the formalin pretreatment likely inhibited the uptake of Lipo-CPFX also alongside inhibiting 
the efflux. In this regard, considering the effects of formalin in increasing the rigidity of the 
NR8383 cell’s plasma membrane, the results were suggestive of Lipo-CPFX fusion with the 
NR8383 cell’s plasma membrane as its uptake mechanism. This is because the formalin solution 
can react with the unsaturated fatty acids of the phospholipids composing the plasma membrane 
leading to more number of saturated fatty acids [Hayat, 2000]. It is this higher ratio of saturated 
fatty acids in the plasma membrane that is likely to increase the rigidity but decrease the fluidity 
of the plasma membrane as the unsaturated fatty acids generally have a lower melting point 
compared to saturated fatty acids [Lawson, 1995]. Such an increase in membrane rigidity is 
suspected to inhibit the fusion of Lipo-CPFX with the NR8383 cells thus overall reducing its 
accumulation. 
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Figure 4.2 Effect of 10 % formalin on the accumulation of (a) CPFX and (b) Lipo-CPFX at 200 
µg/ml into the NR8383 cells at 37 oC, data: Mean± SD, N=3-4, * p < 0.05 
 
 
(a) 
(b) 
* 
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4.3.5 Ciprofloxacin accumulation for CPFX and Lipo-CPFX into the NR8383 cells in the 
presence of empty liposomes at 37 
o
C 
 
The formalin pre-treatment studies suggested that the uptake mechanisms are likely different for 
CPFX and Lipo-CPFX in the NR8383 cells. In this regard, the accumulation of Lipo-CPFX into 
the NR8383 cells was tested in the presence of empty liposomes (with no encapsulated 
ciprofloxacin) to further investigate the difference in their uptake mechanisms. Ciprofloxacin 
accumulation for CPFX in the absence and presence of empty liposomes were not significantly 
different (e.g., 2658.4 ± 174.2 and 2807 ± 706.3 respectively, p > 0.05) at 140 μg/ml. In contrast, 
table 4.3 describes the significantly increased accumulation for Lipo-CPFX (2.2 – 4.3-fold, p < 
0.05) in the presence of empty liposomes at 10 – 200 µg/ml. These suggested that the empty 
liposomes stimulated the uptake mechanisms and/or inhibited the efflux mechanisms for Lipo-
CPFX but not for CPFX. It is known that increasing the phospholipid content of the plasma 
membrane increases the membrane fluidity [Gundermann, 1993]. The addition of empty 
liposomes is believed to result in their incorporation into the NR8383 cell’s plasma membrane 
and increasing the phospholipid content. This incFreased phospholipid content is speculated to 
have increased the fusion of the Lipo-CPFX with the NR8383 cell’s plasma membrane. If so, it 
was reasonable that such an enhancing effect was not observed with CPFX, because its uptake 
was via passive diffusion. 
Also the enhancing effect observed with Lipo-CPFX may have to do with specific properties 
between the phospholipid bilayers of the empty liposomes, Lipo-CPFX and the macrophage 
plasma membrane. It has been reported that the inclusion of cholesterol below the phase 
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transition temperature of the liposomes would result in increased fluidization of the membranes 
[Cullis et al, 1986]. As Lipo-CPFX are composed of phosphatidylcholine and cholesterol 
[Cipolla et al, 2012], it is likely that addition of the empty liposomes could result in an increased 
effect of cholesterol, which can have destabilizing effects on the plasma membrane. Such an 
argument falls in line with the physiological function of cholesterol in the plasma membrane, 
where in it is said to act as a fluidity buffer. At higher temperatures where in the plasma 
membrane tends to become more fluidic and therefore less stable, the cholesterol serves to 
decrease the fluidity by crystallizing the adjacent fatty acid chains of the phospholipids. At lower 
temperatures, wherein the plasma membrane tends to be more rigid, the cholesterol is said to 
increase the fluidity by separating the fatty acid chains from each other [Alberts et al, 2007]. 
Hence, while the exact mechanism of the enhanced Lipo-CPFX accumulation by the empty 
liposomes remains to be identified, it is speculated at this point  that the empty liposomes can 
fuse with the plasma membrane of the NR8383 cells increasing the membrane phospholipid and 
cholesterol content, thus increasing the membrane fluidity and Lipo-CPFX accumulation via an 
enhanced fusion mechanism.  
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Table 4.3 Effect of empty liposome on the accumulation for Lipo-CPFX into NR8383 at 37 
o
C, 
Data, Mean ± SD, N=4, * p < 0.05 
Lipo-CPFX applied 
concentration 
µg/ml 
Average ciprofloxacin accumulated 
mass at 37 
o
C 
(ng per 10
6
 cells) 
Controls + empty liposomes Fold-increase 
10 109.5 ± 17.3 232.7 ± 28.2
*
 2.2 ± 0.4 
20 219.8 ± 35.1 943.7 ± 123.8
*
 4.3 ± 0.4 
40 503.8 ± 60.4 1495.9 ± 399.9
*
 3.0 ± 0.6 
80 985.9 ± 141.2 4067.8 ± 890.0
*
 4.2 ± 0.9 
200 3173.9 ± 180.8 8857.0 ± 783.1
*
 2.8 ± 0.4 
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4.4 Conclusion 
 
In this chapter, the uptake and efflux mechanisms that are likely involved in the ciprofloxacin 
accumulation into the NR8383 cells for CPFX and Lipo-CPFX were explored. Both CPFX and 
Lipo-CPFX appeared to be taken up via non-endocytotic pathways by the NR8383 cells. 
Specifically, CPFX appeared to be taken up diffusion, whereas Lipo-CPFX appeared to be taken 
up via an energy independent fusion process that was dependent on the membrane fluidity of the 
NR8383 cells. Upon uptake, Lipo-CPFX appeared to release the encapsulated ciprofloxacin 
following which it was subject to efflux and/or release from the NR8383 cells. The efflux of both 
CPFX and Lipo-CPFX from the NR8383 cells were shown to be energy dependent and via 
MRP-like transporter(s).  
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CHAPTER 5  
 
SUMMARY AND GENERAL CONCLUSIONS 
 
 
 
In this thesis project, the accumulation of liposomal ciprofloxacin (Lipo-CPFX) into the alveolar 
macrophages was studied in vitro using the NR8383 cells, compared to that of unformulated free 
ciprofloxacin (CPFX) in solution. The project aimed at characterizing the kinetics and 
mechanisms for its greater accumulation (i.e., targeting), which logically led to a greater 
potential to better treat respiratory infections especially caused by microbial accumulation and 
multiplication within the alveolar macrophages. Lipo-CPFX or CPFX were incubated with the 
NR8383 cells in culture, and ciprofloxacin accumulation and efflux were determined by 
fluorescence HPLC under a variety of experimental conditions, such as at different 
concentrations, at a reduced temperature, and in the presence of accumulation/efflux modulators.   
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The time-course profiles of ciprofloxacin accumulation for Lipo-CPFX were bi-phasic at higher 
concentrations, where rapid drug accumulation was followed by efflux prior to reaching the 
asymptotic values at  60 min. While differing from the apparent first-order profiles for CPFX, 
these resulted in greater drug accumulation for Lipo-CPFX, compared to CPFX, at  40 g/ml. 
This initial rapid uptake for Lipo-CPFX was not observed in the presence of NHCl, where acid 
trap of ciprofloxacin was weakened, and the profiles became effectively overlaid to those for 
CPFX. This in turn suggested intact liposome uptake for Lipo-CPFX without release, while 
efflux still occurred in a kinetically identical fashion with that for CPFX. The asymptotic 
accumulation of ciprofloxacin increased proportionally with increasing concentration for Lipo-
CPFX, suggesting no saturable kinetics for this uptake and efflux. This was again different from 
apparently saturable accumulation for CPFX at  80 g/ml, which may have suggested certain 
acid-trapping capacity for ciprofloxacin within the cells upon diffusive uptake. This Lipo-CPFX 
accumulation was increased at a reduced temperature of 4 
o
C and by the use of cell energy-
depleting agents, sodium azide and deoxyglucose. It was likely therefore that the uptake was not 
cell energy-dependent, but efflux, presumably consistent with non-saturable accumulation 
kinetics. In further support, it was shown that Lipo-CPFX accumulation was not increased by 
formalin treatment of the NR8383 cells and increased by 2-4-fold in the presence of empty 
liposomes, which likely suggested lipid fusion uptake rather than endocytosis or phagocytosis. 
Indeed, endocytosis or phagocytosis inhibitors, cytochalasin D, amantadine and chlorpromazine, 
all failed to inhibit the accumulation of Lipo-CPFX into this NR8383 cell system. In contrast, the 
efflux for Lipo-CPFX was rapid and in part cell energy-dependent, mediated through 
probenecid-sensitive transporters, such as multi-drug resistance-like (MRP-like) proteins. This 
was in line with ciprofloxacin release for Lipo-CPFX within the cells upon liposome uptake as a 
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result of lipid fusion, such that efflux was kinetically due largely to ciprofloxacin. In summary, 
Figure 5.1 describes the cellular disposition of uptake and efflux for Lipo-CPFX in the NR8383 
cells, which has been consistent with the results shown in this thesis project.  
 
Figure 5.1 Cellular disposition of uptake and efflux of (a) CPFX and (b) Lipo-CPFX in the rat 
alveolar macrophages NR8383 cells 
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Passage dependent accumulation of CPFX at 140 µg/ml (Figure 3.1 (a)) 
Passage Ciprofloxacin accumulated mass per 10
6
 cells (ng) Mean 
mass 
(ng) 
SD N 
Well 1 Well 2 Well 3 Well 4 
10 790.9 803.1 677.9 556.9 707.2 114.9 4 
15 2646.1 2891.2 2627.3 2469.2 2658.4 174.2 4 
 
Passage dependent accumulation of Lipo-CPFX at 140 µg/ml (Figure 3.1 (b)) 
Passage Ciprofloxacin accumulated mass per 10
6
 cells (ng) Mean 
mass 
(ng) 
SD N 
Well 1 Well 2 Well 3 Well 4 
10 1874.2 1764.6 1850.5 1674.3 1790.9 90.9 4 
15 4082.4 4162.2 4562.1 7156.2 4990.7 1458.8 4 
 
Passage dependent accumulation of CPFX at 200 µg/ml (Figure 3.2 (a)) 
Passage Ciprofloxacin accumulated mass per 10
6
 cells (ng)  
Mean mass (ng) 
 
SD 
 
N 
 
Well 1 
 
Well 2 
 
Well 3 
 
Well 4 
 
 
  
 
10 
 
1249.2 
 
1186.6 
 
949.1 
 
960.9 1086.5 154.0 
 
4 
 
15 
 
3002.9 
 
2566.8 
 
2775.9 
 
2968.5 2828.5 203.0 
 
4 
 
Passage dependent accumulation of Lipo-CPFX at 200 µg/ml (Figure 3.2 (b)) 
Time (minutes) Ciprofloxacin accumulated mass per 10
6
 cells 
(ng) 
Mean mass 
(ng) 
SD N 
  
Well 1 
 
Well 2 
 
Well 3 
 
Well 4 
   
 
 
10 
 
3110.1 
 
3278.5 
 
2950.7 
 
3356.2 3173.9 180.8 
 
4 
 
15 
 
5270.3 
 
5532.2 
 
7689.5 5579.5 6017.9 972.3 
 
4 
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Time course accumulation of 10 µg/ml CPFX at 37 
o
C (Figure 3.3) 
Time (minutes) Ciprofloxacin accumulated mass per 10
6
 cells (ng) Mean 
mass 
(ng) 
SD N 
 Well 1 Well 2 Well 3 Well 4    
5 163.1 149.7 135.8 149.4 149.5 11.1 4 
15 158.5 122.3 156.5 148.7 146.5 16.7 4 
30 187.2 187.2 156.2 136 166.7 25.1 4 
45 140.4 151.5 115.5 182.7 147.5 27.8 4 
60 157 151.2 136.3 123.7 142.1 15.0 4 
120 135.2 156.0 102.2 133.5 131.7 22.2 4 
240 134.9 177.1 177.3 125.9 153.8 27.3 4 
 
 
Time course accumulation of 10 µg/ml Lipo-CPFX at 37 
o
C (Figure 3.3) 
Time (minutes) Ciprofloxacin accumulated mass per 10
6
 cells (ng) Mean 
mass 
(ng) 
SD N 
 Well 1 Well 2 Well 3 Well 4    
5 161.7 154.8 228.9 - 181.8 40.9 3 
15 163 161.6 151.2 165 160.2 6.1 4 
30 195.4 138.4 152.1 155.7 160.4 24.5 4 
45 184.3 137.7 156.1 155.3 158.4 19.3 4 
60 121.6 127 165.8 128.8 135.8 20.2 4 
120 137.1 158.0 155.3 122.2 143.2 16.8 4 
240 132.2 134.3 154.3 191.7 153.1 27.6 4 
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Time course accumulation of 200 µg/ml CPFX at 37 
o
C (Figure 3.3) 
Time (minutes) Ciprofloxacin accumulated mass per 10
6
 cells 
(ng) 
 
Mean mass 
(ng) 
 
SD 
 
N 
  
Well 1 
 
Well 2 
 
Well 3 
 
Well 4 
 
 
  
 
5 
 
430.1 
 
342.4 
 
321.8 
 
506.6 
 
400.2 
 
85.1 
 
4 
 
15 
 
2564.1 
 
2111.5 
 
2562.1 
 
1803.4 
 
2184.9 312.6 
 
4 
 
30 
 
4828.2 
 
4380.3 
 
3876.0 
 
3906.2 4247.7 450.7 
 
4 
 
45 
 
1802.1 
 
2018.5 
 
2297.2 
 
2310.4 2107.1 243.8 
 
4 
 
60 
 
2664.1 
 
2335.6 
 
2370.2 
 
2425.6 2448.9 148.2 
 
4 
 
120 
 
3002.9 
 
2566.8 
 
2775.9 
 
2968.5 2823.5 203.0 
 
4 
 
240 
 
2279.6 
 
2705.5 
 
2722.4 
 
2165.9 2604.3 355.5 
 
4 
 
 
Time course accumulation of 200 µg/ml Lipo-CPFX at 37 
o
C (Figure 3.3) 
Time (minutes) Ciprofloxacin accumulated mass per 10
6
 cells 
(ng) 
Mean mass 
(ng) 
SD N 
  
Well 1 
 
Well 2 
 
Well 3 
 
Well 4 
   
 
 
5 
 
6339.2 
 
6913.9 
 
5595.6 
 
5853.1 
 
6175.5 
 
580.9 
 
4 
 
15 
 
10402.2 
 
7567.05 
 
6668.2 
 
6856.9 7513.3 1700.6 
 
4 
 
30 
 
12218.7 
 
8204.9 
 
10238.7 
 
10332.9 9733.5 1828.6 
 
4 
 
45 
 
7311.9 
 
5402.1 
 
7312.2 
 
6993.2 6214.6 1444.3 
 
4 
 
60 
 
7119.6 
 
5000.7 
 
2838.3 
 
6636.0 5039.9 1856.1 
 
4 
 
120 
 
5270.3 
 
5532.2 
 
7689.5 
 
5579.5 6017.9 1122.7 
 
4 
 
240 
 
5158.5 
 
5736.4 
 
4182.7 
 
4554.3 4609.2 892.5 
 
4 
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Concentration dependent accumulation of CPFX at 37 
o
C (Figure 3.4) 
Concentration 
(µg/ml) 
Ciprofloxacin accumulated mass per 10
6
 cells (ng) Mean 
mass (ng) 
SD N 
 Well 1 Well 2 Well 3 Well 4    
10 122.1 68.0 96.7 74.5 90.3 24.5 4 
20 180.7 229.7 184.2 199.2 198.4 22.3 4 
40 336.7 402.9 360.9 353.4 363.5 28.2 4 
80 723.6 607.6 545.9 611.6 622.1 74.0 4 
120 1041.0 546.3 306.7 698.1 648.0 307.6 4 
140 790.9 803.1 677.9 556.9 707.2 114.9 4 
180 1248.5 1064.9 1166.7 1264.4 1186.1 91.4 4 
200 1249.2 1186.8 949.1 960.9 1086.5 154.0 4 
 
 
 
Concentration dependent accumulation of Lipo-CPFX at 37 
o
C (Figure 3.4) 
Concentration 
(µg/ml) 
Ciprofloxacin accumulated mass per 10
6
 cells (ng) Mean 
mass (ng) 
SD N 
 Well 1 Well 2 Well 3 Well 4    
10 131.8 110.3 106.3 89.7 109.5 17.3 4 
20 238.1 184.8 196.7 259.9 219.8 35.1 4 
40 527.2 423.5 566.3 498.2 503.8 60.4 4 
80 1067.9 821.5 920.7 1133.5 985.9 141.2 4 
120 1501.0 1373.3 1459.3 1287.3 1405.2 94.9 4 
140 1874.2 1764.6 1850.5 1674.3 1790.9 90.9 4 
180 2321.6 2245.9 2250.2 2158.1 2244.0 66.9 4 
200 3110.1 3278.5 2950.7 3356.2 3173.9 180.8 4 
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Time course accumulation of 200 µg/ml CPFX in the presence of 50 mM NH4Cl at 37 
o
C (Figure 
3.5 (a)) 
Time 
(minutes) 
Ciprofloxacin accumulated mass per 10
6
 
cells (ng) 
Mean mass 
(ng) 
SD N 
 Well 1 Well 2 Well 3 Well 4    
15 1817.6 2297.9 2862.3 1969.8 2236.9 462.6 4 
30 2158.9 2861.9 2802.8 2723.9 2636.8 323.6 4 
45 2503.3 2594.0 2677.8 1735.5 2377.7 434.0 4 
60 3423.9 2255.6 2388.9 2659.6 2682.0 522.4 4 
120 2681.1 2303.9 4033.4 2506.2 2881.2 783.5 4 
240 2007.9 1795.7 2216.2 5767.8 2946.9 1888.4 4 
 
 
 
Time course accumulation of 200 µg/ml Lipo-CPFX in the presence of 50 mM NH4Cl at 37 
o
C 
(Figure 3.5 (b)) 
Time 
(minutes) 
Ciprofloxacin accumulated mass per 10
6
 
cells (ng) 
Mean mass 
(ng) 
SD N 
 Well 1 Well 2 Well 3 Well 4    
15 2932.2 2659.0 1712.2 2457.9 2440.4 522.9 4 
30 3734.5 3104.5 3623.6 2753.6 3304.1 458.3 4 
45 3274.6 3017.3 3073.2 1900.2 2816.4 620.7 4 
60 3503.8 3706.2 3341.4 2470.1 3255.4 544.4 4 
120 3188.8 2638.2 3155.0 3118.4 3025.1 259.5 4 
240 2219.8 2639.7 1827.1 1890.6 2144.3 372.4 4 
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Time course efflux following accumulation of 10 µg/ml CPFX at 37 oC (Figure 3.7) 
Time 
(minutes) 
Ciprofloxacin effluxed mass per 10
6
 cells 
(ng) 
Mean mass 
(ng) 
SD N 
 Well 1 Well 2 Well 3 Well 4    
5 50.0 39.9 23.5 58.5 43.0 15.0 4 
10 36.4 33.3 50.1 73.7 48.4 18.4 4 
30 69.5 51.0 77.9 61.2 64.9 11.5 4 
60 74.8 90.1 56.1 102.4 80.9 20.0 4 
90 88.9 89.1 85.1 109.7 93.2 11.1 4 
120 75.3 79.7 87.3 98.8 85.3 10.3 4 
240 96.1 89.1 111.0 89.7 96.5 10.2 4 
 
 
Time course efflux following accumulation of 10 µg/ml Lipo-CPFX at 37 oC (Figure 3.7) 
  
 
  
 
 
 
 
 
Time 
(minutes) 
Ciprofloxacin effluxed mass per 10
6
 cells 
(ng) 
Mean 
mass (ng) 
SD N 
 Well 1 Well 2 Well 3 Well 4    
5 38.6 54.6 53.5 - 48.9 8.9 3 
10 70.2 85.4 49.3 - 68.3 18.1 3 
30 69.0 88.3 58.8 71.6 71.9 12.2 4 
60 75.0 84.3 79.6 72.1 77.8 5.3 4 
90 78.2 90.8 63.1 75.1 76.8 11.4 4 
120 81.3 97.1 70.4 84.3 83.3 11.0 4 
240 82.2 93.5 79.0 104.9 89.9 11.8 4 
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Cumulative % ciprofloxacin mass effluxed following accumulation of 200 µg/ml CPFX at 37 oC 
(Figure 3.8) 
Time (minutes) Cumulative % ciprofloxacin mass per 10
6
 cells  Mean  
(%) 
SD N 
 Well 1 Well 2 Well 3    
5 9.1 21.3 13.4 14.6 6.2 3 
10 35.6 46.2 48.4 43.4 6.9 3 
30 69.5 58.8 65.6 64.6 5.4 3 
60 80.5 64.6 80.5 75.2 9.2 3 
90 100.6 84.3 95.3 93.4 8.3 3 
120 106.1 78.6 83.3 89.3 14.7 3 
240 95.5 82.5 91.6 89.9 6.7 3 
 
 
 
Cumulative % ciprofloxacin mass effluxed following accumulation of 200 µg/ml Lipo-CPFX at 
37 
o
C (Figure 3.8) 
Time 
(minutes) 
Cumulative % ciprofloxacin mass per 10
6
 
cells  
Mean 
(%) 
SD N 
 Well 1 Well 2 Well 3 Well 4    
5 41.0 15.9 42.0 44.8 35.9 13.5 4 
10 59.3 46.5 74.7 53.5 58.5 12.0 4 
30 76.7 67.2 98.0 58.7 75.1 16.9 4 
60 69.2 78.2 84.8 70.1 75.6 7.4 4 
90 90.8 88.9 92.2 71.5 85.8 9.7 4 
120 92.2 111.8 99.0 64.4 91.9 20.0 4 
240 95.4 89.7 83.6 79.6 87.0 6.9 4 
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Cumulative % ciprofloxacin mass effluxed following accumulation of 10 µg/ml CPFX and Lipo-
CPFX at 37 and 4 
o
C (Figures 3.9 (a) and (b)) 
 Cumulative % ciprofloxacin mass per 
10
6
 cells  
Mean 
% 
SD N 
Well 1 Well 2 Well 3 Well 4    
CPFX 
120 minutes, 
37 
o
C 69.7 78.0 71.5 98.6 79.4 13.2 
 
4 
120 minutes, 
4 
o
C 68.6 46.2 - - 57.4 - 
 
2 
240 minutes, 
37 
o
C 89.0 87.1 90.9 89.5 89.2 1.6 
 
4 
240 minutes, 
4 
o
C 72.4 54.1 72.8 81.7 70.2 11.6 
 
4 
Lipo-CPFX 
120 minutes, 
37 
o
C 89.5 93.4 96.4 81.6 90.2 6.4 
 
4 
120 minutes, 
4 
o
C 57.0 74.2 49.4 50.2 57.7 11.5 
 
4 
240 minutes, 
37 
o
C 90.5 82.5 92.8 91.5 89.3 4.6 
 
4 
240 minutes, 
4 
o
C 67.1 71.1 57.2 64.1 64.9 5.9 
 
4 
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Concentration dependent accumulation of CPFX at 4 
o
C (Figure 4.1 (a)) 
Concentration 
(µg/ml) 
Ciprofloxacin accumulated mass per 10
6
 cells (ng) Mean 
mass (ng) 
SD N 
 Well 1 Well 2 Well 3 Well 4 
10 246.3 176.3 129.5 159.2 177.8 49.6 4 
20 284.4 222.6 265.5 279.6 263.0 28.1 4 
40 598.1 544.3 631.5 660.0 608.5 49.7 4 
80 1268.4 1174.9 780.1 927.5 1037.7 224 4 
120 908.7 1421.5 1275.8 1815.9 1355.5 375.2 4 
140 1169.8 1107.4 1995.2 1360.8 1408.3 405.9 4 
180 2287.3 1956.7 1955.7 2525.1 2181.2 277.4 4 
200 2613.4 2339.7 2357.9 1916.3 2306.8 288.8 4 
 
 
Concentration dependent accumulation of Lipo-CPFX at 4 
o
C (Figure 4.1 (b)) 
Concentration 
(µg/ml) 
Ciprofloxacin accumulated mass per 10
6
 cells (ng) Mean 
mass (ng) 
SD N 
 Well 1 Well 2 Well 3 Well 4 
10 184.2 202.5 215.0 220.1 205.4 16.0 4 
20 348.4 317.3 347.8 314.1 331.9 18.8 4 
40 721.3 841.8 827.0 932.5 830.7 86.6 4 
80 2004.2 1692.6 1348.4 1469.5 1628.7 288.1 4 
120 2250.8 1956.0 2079.7 2015.6 2075.5 127.3 4 
140 1955.8 1874.3 2128.3 2259.5 2054.5 172.9 4 
180 2576.1 2257.4 3054.0 2601.1 2622.2 327.7 4 
200 3055.3 3526.4 2976.4 3716.5 3318.7 359.6 4 
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Accumulation of 140 µg/ml CPFX in the presence of inhibitors (Table 4.2 (a)) 
Control+ Ciprofloxacin accumulated mass per 
10
6
 cells (ng) 
Mean 
mass (ng) 
SD N 
 Well 1 Well 2 Well 3 Well 4 
  
50 mM Deoxyglucose 
 
1884.5 
 
1385.2 
 
2371.5 
 
- 1880.4 493.2 
 
3 
 
 5 mM Sodium azide 
 
1349.7 
 
1558.7 
 
1349.8 
 
1483.1 1435.3 103.5 
 
4 
 5 mM Probenecid 1338.6 1596.1 1657.9 1214.5 1451.8 210.1 4 
 100 µM Verapamil 1598.8 2477.3 1659.7 2692 2107.0 559.1 4 
  
25 µg/ml Chlorpromazine 
 
1550.2 
 
1574.9 
 
1972.6 
 
1833.2 1732.7 204.9 
 
4 
 10 µg/ml Cytochalasin D 3058.1 3098.6 3201.1 3016.8 3093.7 79.0 4 
 5 mg/ml Amantadine 
hydrochloride 2405.9 3255.9 2349.4 
 
2263.3 2568.6 461.9 
 
4 
 
 
 
Accumulation of 140 µg/ml Lipo-CPFX in the presence of inhibitors (Table 4.2 (b)) 
Control+ Ciprofloxacin accumulated mass per 
10
6
 cells (ng) 
Mean 
mass (ng) 
SD N 
 Well 1 Well 2 Well 3 Well 4 
 
50 mM Deoxyglucose 
 
3263.1 
 
3050.4 
 
2835.3 
 
3510.0 3164.7 288.9 
 
4 
 
5 mM Sodium azide 
 
3146.5 
 
2449.0 
 
2636.2 
 
2602.8 2708.6 303.1 
 
4 
5 mM Probenecid 1825.5 2794.5 2165.7 2414.1 2300.0 408.5 4 
100 µM Verapamil 6381.2 6255.0 5567.2 6690.5 6223.5 474.2 4 
 
25 µg/ml Chlorpromazine 
 
2065.5 
 
3786.8 
 
2619.9 
 
2470.7 2735.8 738.8 
 
4 
10 µg/ml Cytochalasin D 3770.1 3562.4 4216.3 4282.7 3957.9 348.3 4 
5 mg/ml Amantadine 
hydrochloride 
 
2319.2 
 
2210.7 
 
2092.3 
 
2103.2 2181.4 106.3 
 
4 
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Accumulation of CPFX and Lipo-CPFX following 10 % formalin treatment (Figure 4.3 (a) and 
(b)) 
Formulation Ciprofloxacin accumulated mass per 10
6
 cells (ng) Mean 
mass (ng) 
SD N 
Well 1 Well 2 Well 3 Well 4 
200 µg/ml 
CPFX 
 
1577.5 
 
1813.4 
 
1327.7 
 
- 1572.9 242.9 
 
3 
200 µg/ml 
Lipo-CPFX 
 
2281.8 
 
2600.0 
 
2514.7 
 
2932.2 2582.2 269.3 
 
4 
 
 
 
 
Accumulation of CPFX and Lipo-CPFX in the presence of empty liposomes (Table 4.3) 
Formulation Ciprofloxacin accumulated mass per 10
6
 cells (ng) Mean 
mass (ng) 
SD N 
Well 1 Well 2 Well 3 Well 4 
10 µg/ml 
Lipo-CPFX 
 
235.5 
 
269.7 
 
202.2 
 
223.6 232.7 28.2 
 
4 
20 µg/ml 
Lipo-CPFX 
 
1035.6 
 
903.4 
 
786.4 
 
1049.3 943.7 123.8 
 
4 
40 µg/ml 
Lipo-CPFX 
 
1192.3 
 
1110.2 
 
1873.6 
 
1806.6 1495.9 399.9 
 
4 
80 µg/ml 
Lipo-CPFX 
 
5337.5 
 
4032.2 
 
3478.4 
 
3423.0 4067.8 890.0 
 
4 
200 µg/ml 
Lipo-CPFX 
 
9901.7 
 
8033.9 
 
8899.1 
 
8593.4 8857.0 783.1 
 
4 
140 µg/ml 
CPFX 
 
2366.1 
 
2466.0 
 
2534.7 
 
3861.4 2807.1 706.3 
 
4 
 
 
 
